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1 Executive summary  
Aim 
The aim of this guidance document is to provide EU/EEA Member States and EU bodies with relevant information 
to make an informed decision on routine vaccination of healthy children and pregnant women with seasonal 
influenza vaccine. The options presented in this document are based on a systematic review of the literature and 
the opinions of a group of independent experts; the expert group also provided additional literature.  
The aims of the systematic review were to collect, critically appraise and summarise: 
• European data and data from other Western countries on burden of seasonal and pandemic influenza (e.g. 
incidence, hospitalisations, mortality, and complications) in children and pregnant women; 
• European data and data from other Western countries on burden of seasonal and pandemic influenza in 
young children when their contacts are vaccinated;  
• European data only on the safety, efficacy, effectiveness and cost effectiveness of available seasonal and 
pandemic influenza vaccines in children and pregnant women.  
Methods 
PubMed and Embase were used to collect relevant articles that were published between August 2000 and August 
2010 and contained data collected in the year 2000 or later (i.e. articles that contained only data from before the 
year 2000 were excluded). Furthermore, an additional PubMed search for articles from three key authors (i.e. Fiore 
AE, Jamieson DJ, Neuzil KM) was undertaken, and some additional articles were retrieved by hand search (i.e. 
identified in another included paper) and other databases. Since annual vaccination of children with known risk 
factors for severe influenza is recommended in all EU countries, this topic was not included in the systematic 
literature review; nevertheless it was discussed at an expert meeting.  
All possible relevant papers were critically appraised using the CoCanCPGi checklists (Annex V). Articles judged to 
be of insufficient quality were excluded. Examples include:  
• reviews or meta-analyses in which no description of the methodology was included, or the search was not 
sufficiently rigorous to identify all relevant articles;  
• randomised controlled trials in which the randomisation process was not described or not well executed, 
which could lead to bias;  
• a surveillance study in which the source population was not well defined.  
A meeting with experts from Europe and the USA was held in Stockholm on 15 and 16 June 2011.  
In preparation of the meeting, the experts read the report of the systematic review. Furthermore, the experts 
could provide literature, or data from other data sources in addition to the literature and data included in the 
systematic review. During the expert meeting, the following topics were discussed: burden of influenza in children 
and pregnant women, vaccine effectiveness and safety, main pros and cons with regard to vaccination of these 
groups in the European context, and gaps in knowledge.  
  
 
                                                                    
i The CoCanCPG (Coordination of Cancer Clinical Practice Guidelines) was originally designed for developing cancer guidelines, but 
the criteria are also applicable to studies that address other research questions. 
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Results and conclusions 
What are the advantages and disadvantages of the following vaccine strategy options in the European context?  
Universal immunisation of all children aged six months to 18 years without contraindications to 
vaccination.  
Pros:  
• Universal immunisation can potentially reach children who have underlying conditions, but are unaware of 
these and would be missed by targeted vaccination programmes.  
• Vaccinating all children would lead to herd immunity thus reducing overall transmission of influenza. The 
extent of herd immunity produced by different immunising schedules has been estimated by mathematical 
modelling. However, herd immunity is difficult to investigate and there is little data available on herd 
immunity after influenza vaccination.  
Cons: 
• The burden of influenza in children five to 18 years old is considerably lower than the burden in younger 
children. Therefore the benefits of also vaccinating older children will be lower compared with only 
vaccinating children aged six months to four years, since fewer hospitalisations/deaths can be prevented.  
Universal immunisation of children aged six months to four years without contraindications to 
vaccination.  
Pros:  
• The literature review found that the burden of influenza in Western countries is higher in children aged six 
months to four years than in children aged five to 18 years.  
• Data from non-European studies suggested that influenza hospitalisations in children aged six months to 
four years are comparable with that in elderly or adults with underlying conditions, for whom vaccination is 
recommended in Europe. 
• Assuming the vaccine is effective in children, it can be inferred that vaccination of all children aged six 
months to four years would lead to a reduction of the major influenza complications in this age group, e.g. 
secondary bacterial infections such as pneumonia and otitis media. This could be an important consideration 
especially in countries that have high levels of antibiotic resistance.  
Cons: 
• When countries consider introducing universal influenza vaccination of children, special attention should be 
paid to how this could affect the overall childhood vaccination schedule. This can vary from country to 
country; specific studies to assess parental attitudes towards influenza vaccination, and towards vaccination 
in general, can be helpful in this context.  
• Hardly any European studies on vaccine effectiveness in children have been identified and there are no 
post-vaccine safety studies.  
Targeted immunisation of all children aged six months to 18 years with known risk factors.  
Pros:  
• All the consulted experts agreed that children with underlying conditions should be vaccinated against 
seasonal influenza.  
• Although the type of underlying conditions and risk factors for severe influenza infection are well defined, 
new categories may be included as more evidence emerges (e.g. obesity after the 2009 A(H1N1) pandemic).  
Annual influenza vaccination of all pregnant women without contraindications to vaccination. 
Pros: 
• Vaccination could reduce the number of influenza-related hospitalisations and deaths in this group.  
• Vaccination of pregnant women can potentially reduce the burden of influenza in children younger than six 
months old (for whom influenza vaccination and antiviral treatment are not indicated) in two ways:  
− vaccination during pregnancy would reduce the risk of being infected after delivery, thus also 
reducing the risk of transmission to the child during the first months of life; 
− an RCT conducted in Bangladesh showed proof of concept that transmission of influenza antibodies 
from the mother to the child takes place and protects the child. Influenza vaccination of the mother 
during pregnancy was shown to confer protection to the infants also in a number of observational 
studies. Finally, because both the use of antiviral therapy as well as influenza vaccine are not 
indicated for use in children younger than six months, there is lack of alternatives to protect these 
children against influenza, while burden is this group is known to be high.  
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• Vaccination could reduce the need to treat pregnant women with antivirals. Treatment with antivirals might 
in theory be more risky than exposure to an inactivated vaccine for which at the moment there are no 
indications that this causes harm.  
• Assuming the vaccine is effective, it may also reduce influenza complications such as secondary bacterial 
infections. This could be especially important in countries that have high levels of antibiotic resistance.  
• During influenza pandemics pregnant women are known to have higher hospitalisation and mortality rates 
than what should be expected based on population pregnancy rates; this was also observed during the 
2009 A(H1N1) pandemic.  
• The general view of most experts was that the advantages of vaccinating healthy pregnant women are valid 
and supported by evidence.  
• Although there are no European data on influenza vaccine effectiveness in pregnant women, it can be 
inferred that vaccine effectiveness is similar to that of healthy women of childbearing age. 
Cons: 
• Most of the evidence supporting this scientific advice comes from non-European data. More evidence, e.g. 
from active surveillance systems or large cohort studies, is needed from Europe.  
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2 Background, aim, expert selection 
Background 
In 2008, ECDC published an article on risk groups for seasonal influenza, i.e. groups who, if infected with influenza, 
are more likely to experience severe diseaseii. This publication was based on the conclusions of a scientific panel 
that had examined the immunisation of children and concluded that, at the time, data were insufficient to 
formulate an opinion on childhood vaccination in Europeiii.  
A Recommendation of the European Union (EU) Health Council issued in December 2009 essentially recommended 
the increased vaccination of risk groups and healthcare workers by the Member States. This Recommendation 
entailed that ECDC provided guidance on risk groups, in addition to further technical and scientific expertiseiv.  
In an article written by ECDC scientists on ‘preliminary guidance for developing influenza vaccination 
recommendations’ and published after the 2009 pandemic, the authors argued that the emergence of a new group 
of viruses (i.e. A(H1N1)pdm09) might change the scientific basev.  
Today, two areas of particular uncertainty remain, namely whether to offer immunisation to children and pregnant 
women (aside from those with underlying medical conditions).  
It should be noted that under its mandate ECDC generally does not issue recommendations; instead, it issues 
guidance which assists Member States and EU bodies in producing recommendations. Hence the requirement for 
this guidance was an internal decision of ECDC as part of its ongoing scientific work and in response to the 2009 
EU Council Recommendation.  
Aim 
The aim of this guidance document is to provide EU Member States with relevant information to help in the 
decision-making process on routine vaccination of healthy children and pregnant women with seasonal influenza 
vaccine. The options presented in this document are based on a systematic review of the literature and the 
opinions of a group of independent experts; the expert group also provided additional literature. 
Consulted experts 
A meeting with international experts was held in Stockholm on 15 and 16 June 2011.  
Process of expert selection 
As a first step, the ECDC Candidate Expert Directoryvi was searched for experts with specific expertise in influenza 
vaccination of children and/or pregnant women. The European Influenza Surveillance Network was also searched 
using the same criteria. Additional experts were identified by looking at the authors of the articles included in the 
systematic literature review. An additional Swedish expert with a background in obstetrics and experience in 
administering influenza vaccines to pregnant women was identified by consulting with the person in charge of 
influenza at the National Board of Health and Welfare in Stockholm.  
 
                                                                    
ii Nicoll A, Ciancio B, Tsolova S, Blank P, Yilmaz C. The scientific basis for offering seasonal influenza immunisation to risk groups 
in Europe. Euro Surveill. 2008 Oct 23;13(43). pii: 19018. Available from: 
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19018 
iii Technical report of the scientific panel on vaccines and immunisation. Infant and children seasonal immunisation against 
influenza on a routine basis during inter-pandemic period. ECDC: Stockholm; 2007. Available from: 
http://ecdc.europa.eu/en/publications/Publications/0701_TER_Scientific_Panel_on_Vaccines_and_Immunisation.pdf 
iv Council of the European Union. Council Recommendation of 22 December 2009 on seasonal influenza vaccination (Text with 
EEA relevance)(2009/1019/EU). Official Journal of the European Union. 2009. L 348/71. Available from: http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF 
v Nokleby H, Nicoll A. Risk groups and other target groups – preliminary ECDC guidance for developing influenza vaccination 
recommendations for the season 2010-11. Euro Surveill. 2010 Mar 25;15(12). pii: 19525. Available from: 
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19018 
vi http://ecdc.europa.eu/en/aboutus/external_experts/Pages/external_experts.aspx 
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Experts were included based of the following criteria:  
• experience in running influenza vaccination programmes for children in a European country; 
• experience in issuing seasonal or pandemic influenza vaccine recommendations for pregnant women in a 
European country;  
• international expertise in the field of influenza vaccination of children and pregnant women as documented 
by their publication record.  
Members of the ECDC Advisory Forum were asked whether they had any objections to the proposed expert from 
his/her country. ECDC invited the expert if there were no objections; otherwise, a different expert was selected.  
All experts completed the standard ECDC Annual Declaration of Interest. All declarations were approved by ECDC, 
and are kept on file at ECDC; they are available on request by writing to influenza@ecdc.eurpoa.eu.  
Two ECDC influenza experts were involved in moderating the discussion during the meeting and in writing and 
reviewing the scientific advice/opinion. Two experts from Pallas health research and consultancy B.V. in the 
Netherlandsvii acted as rapporteurs and wrote the first draft of the meeting report and the current document.  
Table 1. List of participants 
Surname First name Institute Country Date of participation 
Ciancio Bruno ECDC Sweden 15 and 16 June 
Leino Tuija National Institute for Health and Welfare Finland 15 and 16 June 
Mangtani Punam London School of Hygiene and Tropical 
Medicine  
UK 15 and 16 June 
Neuzil Kathleen University of Washington, PATH USA 15 and 16 June 
Nicoll Angus ECDC Sweden 15 and 16 June 
Pettersson Karin Karolinska Institute Sweden 15 and 16 June 
Sande van der Marianne RIVM (National Institute for Public Health 
and the environment) 
The Netherlands 16 June by TC 
Shindo Nahoko WHO Switzerland 15 and 16 June 
On June 15, the topics with regard to children were discussed; on June 16, the participant discussed topics related 
to pregnant women.  
Evidence assessment 
The advice provided in this report is based on the following type of evidence: 
• Evidence from a systematic literature review. 
• The opinion of an independent group of experts established by ECDC. 
• Evidence identified by the group of independent experts but not included in the systematic review because 
it was outside of its scope (i.e. articles published earlier or later than the inclusion period of the review).  
  
 
                                                                    
vii www.pallashrc.com 
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3 Systematic review  
Aims 
The aims of the systematic review were to collect, critically appraise and summarise: 
• European data and data from other Westernviii countries on burden of influenza (e.g. incidence of influenza-
like illness (ILI), hospitalisations, mortality, and complications) in children and pregnant women; 
• European data and data from other Western countries on the burden of influenza in young children when 
their contacts are vaccinated;  
• European data only on the safety, efficacy, effectiveness and cost effectiveness of available seasonal and 
pandemic influenza vaccines in children and pregnant women.  
Methods 
PubMed was used as the core database for the systematic review. Embase was also used for the third aim and for 
the burden of influenza in pregnant women because literature on this topic was scarce. The PubMed search was 
conducted for aims 1 and 3 on 28 July 2010, and for aim 2 on 6 October 2010. The Embase search was conducted 
on 6 October 2010.  
Search strings were created for influenza, geographical scope, burden of influenza, vaccine safety, vaccine 
effectiveness, and cost effectiveness. These search strings were combined with search strings for population, i.e. 
children, pregnant women and contact of young children. For a detailed description of the search strategies, please 
refer to Annex 1.  
Case reports were excluded. Papers were included if they were published in English, French, German, Italian, 
Spanish or Dutch between August 2000 and August 2010.  
Articles that were published after the year 2000 but included only data from before the year 2000 were excluded. 
If an article included data from before the year 2000 but also covered susequent years, the article was included.  
The results of the PubMed and Embase search were complemented with: 
• a search on three relevant key authors in this area: AE Fiore, DJ Jamieson and KM Neuzil: one additional 
paper to PubMed/Embase on burden of influenza in pregnant women was added;  
• a hand search: references of selected articles in the systematic search were checked for additional relevant 
articles; 
• other data sources: 
− European Medicine Agency: www.ema.europa.eu;  
− ESWI (European Scientific Working group on Influenza): www.eswi.org  
− European Centre of Disease Prevention and Control: www.ecdc.europa.eu  
− European Influenza Surveillance Network (EISN): 
http://www.ecdc.europa.eu/en/activities/surveillance/EISN/Pages/home.aspx  
− EUVAC: www.euvac.net  
− EuroFlu (WHO/Europe Influenza Surveillance): http://www.euroflu.org/index.php  
− Google: www.google.com, with a search on country name + ‘influenza’ + if necessary, key words 
from the review objectives such as ‘surveillance’, ‘mortality’, ‘morbidity’. 
− local national institutes of public health or ministries of health of the countries, for which the Google 
search did not lead to relevant institutes or data; 
− the library of ECDC’s influenza team.  
Two researchers independently selected articles of possible relevance for the review. These selected articles were 
critically evaluated on quality, using the CoCanCPGix checklists (Annex 5). If there was no consensus between the 
two researchers on whether an article should be included, the article was discussed with a third expert. Articles of 
insufficient quality were excluded. Examples of insufficient quality were:  
• reviews or meta-analyses which lacked a proper description of the methodology; 
• reviews or meta-analyses where the search was not sufficiently rigorous to identify all relevant articles; 
 
                                                                    
viii ‘Western countries’ include European countries, the US, Canada, Australia, New Zealand and Japan (high-income countries 
sharing same economic values, in contrast with middle- and low-income countries).  
ix The CoCanCPG (Coordination of Cancer Clinical Practice Guidelines) was originally designed for developing cancer guidelines, 
but the criteria are also applicable to studies that address other research questions. 
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• randomised controlled trials which did not describe the randomisation process or were judged to not be well 
executed, which could lead to bias; 
• surveillance studies without well defined source populations.  
The systematic review yielded a total of 2754 unique articles, of which 496 were selected in the first selection step 
(i.e. based on title and abstract; the papers that were not selected at this stage did not contain data relevant for 
this review). Of these 496 articles, 87 were included in evidence tables and text, 78 were not available, and 331 
were excluded (i.e. these were of insufficient quality, or did not contain relevant data). The funding source was not 
considered during the selection phase. Please refer to Annex 2 for an overview of the reasons for exclusion.  
Articles reporting data from the 2009 pandemic and those from earlier influenza seasons were summarised 
separately for two reasons: 
• There were significant differences in the risk of severe illness by age and risk group between the two 
periods. 
• During the 2009 pandemic, surveillance than during the years before, which led to an increased number of 
publications on surveillance data. 
Level of evidence 
Included studies were ascribed a level of evidence (see Annex 3). This system is used in the Netherlands (CBO, 
Dutch Institute for Healthcare Improvement) for evidence-based medicine. As surveillance studies are usually not 
included in such systems, we do not provide a level of evidence for surveillance studies (i.e. studies on burden of 
influenza).  
Limitations  
There are several gaps in the literature, some of which are due to restricting the systematic literature review to the 
past ten years. In general, most European studies refer only to western European countries, while data from 
eastern European Union countries are lacking. Instead, available evidence and systematic reviews often came from 
other Western countries, and from expert opinions based on studies conducted before the year 2000.  
Articles written in languages other than English, French, German, Italian, Spanish or Dutch may have been missed, 
which could have disproportionally affected the number of retrieved articles on or from countries in eastern Europe. 
Data on burden of influenza in pregnancy were largely limited to the pandemic, especially when the data were 
provided by EU countries. No burden-of-disease studies were found with data on the vaccination of household 
contacts of young children. Also, no European studies were found which contained data on influenza vaccine 
efficacy/effectiveness or vaccine safety in pregnant women. In general, European data on vaccine effectiveness in 
children are limited.  
Additional evidence provided by the group of experts 
The experts were encouraged to provide additional scientific literature or data from other sources in addition to the 
literature and data included in the systematic review. Some experts submitted papers that were out of scope of the 
systematic review, e.g. the articles either referred to other countries than the ones included in the review or were 
published before 2000/after August 2010. This additional literature was discussed during the expert meeting and 
included if considered relevant for the purposes of this guidance.  
Expert meeting 
A meeting with international experts identified by ECDC was held in Stockholm on 15 and 16 June 2011. In 
preparation for the meeting, the experts had already read the systematic literature review and reviewed the 
following questions:  
Questions concerning children 
1. What is the evidence for and against routine influenza vaccination of all children below the age of 18 years in EU 
countries? 
• Burden of disease  
• Vaccine effectiveness 
• Vaccine safety 
• Knowledge gaps in all of the above 
2. What are the advantages and disadvantages of the following two vaccine strategy options in the European 
context? 
• Targeted vaccination of all children with known risk factors  
• Vaccination of all children without contraindications to vaccination 
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3. Is it possible/convenient to differentiate the vaccination strategy by age group in order to narrow the age 
groups for whom universal vaccination might be advisable? 
4. What is the best vaccination strategy to protect infants below the age of six months for whom there is no 
indication for influenza vaccination? 
• Vaccination of pregnant women (any data on optimal pregnancy period?) 
• Vaccination of contacts 
5. What are the main knowledge gaps and areas of uncertainty that require additional research?  
Questions concerning pregnant women 
1. What is the evidence for and against influenza vaccination of all women who are pregnant during the periods of 
influenza circulation regardless of the pregnancy trimester and the presence of co-morbidities? 
• Burden of disease 
• Vaccine effectiveness 
• Vaccine safety 
• Knowledge gaps in each of the above 
2. What are the main knowledge gaps and areas of uncertainty that require additional research?  
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4 Scientific advice: vaccination of children 
This section reviews the specific questions for and against vaccinating children and pregnant women (see end of 
Section 3 above). For each topic, the results of the systematic review are described first, followed by evidence 
gleaned from additional literaturex as provided by the experts. At the end of each topic, a summary of further 
expert comments as expressed during the meeting is given.  
Annex 3 provides a summary of data as taken from the articles included in the systematic review. The tables in 
Annex 3 do not include data from any of the additional articles that were added by the experts.  
4.1 What is the evidence for and against routine influenza 
vaccination of all children ages 18 years and youngerin EU 
countries?  
a) Burden of disease: evidence from the systematic literature review 
The articles selected in the systemic review on burden of influenza in children are summarised in Annex 3, Tables 2 
to 17.  
2009 pandemic 
In the included European studies, children younger than one year of age and children 0−4 years old showed either 
the highest hospitalisation rate or the highest proportion of cases attributed to influenza1-3. A study by Cullen et al. 
showed similar hospitalisation rates in children 0−4 years and 15−19 years old4. 
The included studies from other Western countries also showed that children below the age of one and children 
0−4 years old had the highest hospitalisation rates or proportion of cases5-12.  
In absolute numbers, mortality was low. In three out of five included European studies, none of the children 
died4;13;14. Van ‘t Klooster et al. showed one death per 200 000 population in children 0−4 and in children 5−14 
years old3. Donaldson et al. estimated that the highest case fatality rate would be in children 0−4 years old15. Over 
the entire pandemic period in England, four (1%) of 336 fatal pandemic cases were reported in children under six 
months of age16.  
Studies from other Western countries showed mortality rates of one in 300 000 to 500 000 population in children 
0−4 years of age7;17;18. The New South Wales Network found that the highest mortality was in children 5−9 years 
old (1 per 500 0009). Paine et al. showed that the proportion of fatal cases of age-specific notified influenza was 0 
to less than 1%10.  
Seasonal influenza 
One European case series study included in the literature review compared influenza-related hospitalisations in 0–
5- and 5–16-year-old children during the influenza seasons 1996/97 to 2001/0219: children below five years of age 
showed the highest proportion of hospitalisation for influenza (81.3%).  
The studies from other Western countries showed that children younger than six months20-31 and children 0–4 
years old had the highest hospitalisation rates compared with older children20-30.  
None of the children of 0–4 years old in the included European studies on hospitalised children died of laboratory-
confirmed influenza32-34. No studies on mortality in older children were found. Mortality was also a rather rare 
subject in the included studies from other Western countries. Two studies found no deaths in children20;35; the 
other studies found that mortality was higher in children 0–4 years old than in older children24;26;36.  
Additional literature identified by the experts  
2009 pandemic 
In November 2010, the Lancet published an update of a paper by Donaldson et al.15 which describes paediatric 
mortality during the 2009 pandemic in England. The authors identified all paediatric deaths in England related to 
pandemic influenza infection from 26 June 2009 to 22 March 2010 through daily reporting systems and cross-
checking of records. Influenza infection was confirmed by laboratory results or death certificates. In the study, 
case fatality and population mortality rates were highest in children below the age of one. The mortality rate in 
children older than one year of age was 14 per 1 000 000. The mortality rate in children 1−17 years old ranged 
 
                                                                    
x This additional material does not constitute a complete and systematic overview of the literature.  
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between four and eight per 1 000 000. Children with severe pre-existing disorders accounted for 64% of all 
deaths.37  
Seasonal influenza 
Johnson et al. reported on seventeen fatal cases of laboratory-confirmed influenza A in children below 18 years of 
age in the UK during the 2003/04 influenza season. The median age of fatal cases was two years, with a range 
from four months to seventeen years. The majority (64%) were under five years of age. Among the sixteen cases 
for which underlying health status information was available none was recorded as having a known risk factor for 
severe influenza. During the 2003/04 season, population morbidity rates in young children of up to four years of 
age were more than twice those of the overall all-age morbidity, indicating substantial disease burden in the 
young38. 
In the US during the 2003/04 season, 153 influenza-associated deaths among children were reported by 40 State 
health departmentsxi. The median age of the children was three years, and 96 of them (63%) were younger than 
five years old. Among the 149 children for whom information on underlying health status was available, 70 (47%) 
had previously been healthy, 49 (33%) had an high-risk medical condition, and 30 (20%) had other chronic 
medical conditions not defined as conferring a high risk39.  
Further expert comments  
• Burden of influenza in children has been measured using various outcomes such as number of ambulatory 
visits for a respiratory infection, hospitalisation and mortality. In order to obtain precise estimates of the 
burden of influenza these outcomes should be laboratory confirmed. In clinical practice laboratory testing is 
not routinely performed in children with respiratory infections or complications. Reasons include that testing 
is not routinely used to guide treatment unless results are rapidly available or because influenza is not 
always suspected as the cause of illness. But even if laboratory tests are conducted, results can be 
misleading: by the time the illness occurs and influenza is considered as the underlying cause, the virus may 
have already been cleared from the respiratory tract.  
Although incidence of influenza-related deaths remains an important criterion for making decisions on the 
vaccination of children, caution in interpreting these data is advisable: deaths directly attributed to influenza 
are reported infrequently, and the numbers of deaths provided in these studies are most likely 
underestimates of the true burden of disease. Hospitalisations are reported more frequently, and because of 
the high cost, hospitalisation is responsible for the largest part of the burden in the various studies. 
Finally, the high number of hospitalisations, especially during the pandemic, should be interpreted with 
caution because they may have been influenced by other factors than severity of disease. For instance 
during the 2009/10 pandemic, young children were probably more likely to be hospitalised than during a 
normal influenza season because parents and clinicians were concerned about unknown risks.  
It should also be noted that paediatric hospital stays during the 2009 pandemic were often short (one to 
two days), and the most frequent reason for admission was exacerbation of asthma. Reducing 
hospitalisations might also partly be achieved by reducing unnecessary admission to hospital care. 
• A large proportion of the burden of influenza is not apparent through surveillance, partially for the reasons 
already mentioned above, but also because many parents do not visit a doctor when their child has 
influenza-like illness. 
• Among children, the youngest age groups (i.e. under five years of age) have the highest incidence of 
disease.  
• The number of influenza-related hospitalisations in children younger than five years of age was comparable 
with the burden in older US adults (over 65 years) or adults with underlying conditions and for whom 
vaccination is recommended; similar comparative studies have not been conducted in Europe.  
b) Vaccine effectiveness and efficacyxii: European evidence from the 
systematic literature review 
Three additional studies describing the efficacy of influenza vaccination in children are shown in Table 21. Vaccine-
efficacy ranged from 22% to 33% in preventing influenza-like-illnesses40, and from 83.5% to 88.4% in preventing 
laboratory-confirmed influenza41;42.  
 
                                                                    
xi In the United States, the reporting of deaths associated with laboratory-confirmed influenza is mandatory. See 
http://www.cdc.gov/flu/weekly/overview.htm   
xii Efficacy – an estimate of the likelihood of preventing laboratory-confirmed influenza under optimal circumstances through 
vaccination – is usually determined through randomised controlled trials. 
Effectiveness – the likelihood of preventing laboratory-confirmed influenza through vaccination when applied in the field – is 
usually determined by observational studies. 
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Additional literature identified by the experts 
At the time of the systematic literature review no European studies on vaccine effectiveness in children were found. 
In October 2011, a phase III randomised clinical trial was published43. The study was conducted during two 
influenza seasons: 2007/08 in Germany (654 children), and 2008/09 in Germany (2104 children) and Finland (1949 
children). The study assessed the safety and efficacy of an MF59-adjuvanted vaccine by comparing it to TIV and a 
placebo in children between six and less than 72 months of age. The absolute vaccine efficacy rates against all 
influenza strains were 86% (95% CI, 74 to 93) for the MF59-adjuvant vaccine (adjuvanted TIV), and 43% (95% CI, 
15 to 61) for the vaccine without the adjuvant (TIV); the relative vaccine efficacy rate for adjuvanted TIV versus 
TIV was 75% (95% CI, 55 to 87). The rates of systemic and local reactions to the influenza vaccines with and 
without the adjuvant were similar in the younger age group (relative risk, 1.04; 95% CI, 0.98 to 1.09), but 
systemic events in the older age group were more frequent after administration of adjuvanted TIV (63%) than 
after administration of TIV (44%) or the control vaccine (50%). Serious adverse events were distributed evenly 
across all three vaccine groups.  
Neuzil (one of the independent experts serving on ECDC’s expert group panel) and Edwards44 reviewed the safety, 
immunogenicity, and efficacy of influenza vaccines in children and discussed the theoretical advantages and 
disadvantages of a more widespread use of vaccines in healthy and high-risk children. Clinical trials and post- 
licensure experience have demonstrated that trivalent inactivated influenza vaccine is well-tolerated in children, 
and the efficacy of the inactivated vaccine has been demonstrated in numerous clinical trials. A large clinical trial 
demonstrated the tolerability and efficacy of the trivalent live attenuated influenza vaccine (LAIV) in children 15 to 
71 months of age. The included studies are mostly non-European studies.  
Gruber et al.45 included 189 school-age children (3−18 years) in a double-blind trial which provided heterotypic 
protection of 62% and compared it with the protection afforded by a placebo consisting of the influenza B/USSR 
component of trivalent inactivated vaccine. A single dose of trivalent inactivated vaccine protected school-age 
children (6 to 19 years of age) from influenza B infection; the rate of protection was 64% against infection and 
73% against febrile illness.  
In a randomised and blinded pilot study by Hurwitz et al.46 conducted during the 1996/97 winter flu season, 
influenza (split virus) trivalent inactivated vaccine was administered to children attending daycare centres. Vaccine 
efficacy in preventing serologically proven influenza virus infection was 45% (95% CI, -2 to 69) for influenza B, 
and 31% (95% CI, -95 to 73) for influenza A(H3N2).  
Hoberman et al.47 conducted a randomised, double-blind, placebo-controlled trial in 786 children aged 6 to 24 
months. The efficacy of the vaccine against culture-confirmed influenza was 66% (95% CI, 34 to 82) in 1999/2000, 
and −7% (95% CI, −247 to 67) in 2000/01. Influenza attack rates differed between these two periods. In 
1999/2000, culture-proven influenza was identified in 5.5% of the children in the vaccine group and in 15.9% of 
the children in the placebo group. In 2000/01, 3.6% of the children in the vaccine group had culture-proven 
influenza versus 3.3% of the children in the placebo group. Small power and a low attack rate in 2000/01 resulted 
in a broad 95% confidence interval (−247 to 67) and the inability to detect a difference between the vaccine and 
placebo group.   
Further expert comments  
• The effectiveness of vaccines can differ between years because of the different strains circulating in the 
population. The effectiveness of vaccines is partly dependent on the degree of matching between the pre-
determined influenza strain used in the vaccine and the circulating vaccine types.  
• Even if an influenza vaccine is less effective than desired, vaccination is still the most effective preventive 
strategy for severe influenza; vaccination has also been shown to reduce hospitalisation in children.  
• Evidence on vaccine efficacy and effectiveness in children is limited. Data from available studies show an 
efficacy/effectiveness comparable to that in the elderly.  
• All experts present agreed that children aged six months to 18 years with underlying conditions should be 
vaccinated against seasonal influenza.  
c) Vaccine safety: evidence from the systematic literature review 
The articles selected in the systemic review on vaccine safety are summarised in Annex 3 (Table 20). 
Overall, the vaccines described in the included literature were well-tolerated; adverse reactions were usually mild 
or moderate40;42;48-51. Of the six studies included, four used trivalent inactivated vaccine (TIV), one used cold-
adapted influenza vaccine, trivalent (CAIV-T), and one used live attenuated influenza vaccine (LAIV)xiii. Few 
significant differences between vaccine and control groups were found. In the study of Vesikari et al.50;51 in Finland, 
children received two doses of Sub/MF59 vaccine (TIV) in the first year and a booster dose one year later. After 
 
                                                                    
xiii Kanra et al. (2004)48 only mention the vaccine’s brand names, not their type. Information on the vaccines was retrieved from 
the manufacturer’s website.  
 
 
 
 
ECDC scientific advice on seasonal influenza vaccination of children and pregnant women TECHNICAL REPORT 
 
 
 
12 
 
 
 
the first and second vaccine dose a significant difference in injection site swelling was found between the 
Sub/MF59 and split group (p=0.033). A significant difference in injection site pain in children ≥ three years was 
reported between the Sub/MF59 and split group (p<0.01) after the third vaccine dose. In another study in Finland, 
a runny nose or nasal discharge occurred in significantly more CAIV-T recipients (82.3%), compared with placebo 
recipients (75.4%) after the first dose in year one (p=0.001)42. Furthermore, in the CAIV-T group, nine possibly, 
probably, or definitely serious events related to study vaccination were reported compared with five events in the 
placebo group in the first year of the study. This difference was not statistically significant (P value not reported). 
In the second year there were two events judged to be possibly, probably, or definitely related to study vaccination 
in the CAIV-T group. It was not reported in the article whether there were events in the placebo group. No deaths 
occurred in the included studies.  
Additional literature identified by the experts 
The experts provided no additional literature.  
Further expert comments  
Finland and Sweden observed cases of narcolepsy occurring after vaccination with Pandemrix (an AS03-adjuvanted 
pandemic vaccine) during the 2009 A(H1N1) pandemic. In Europe, a multi-country case-control study is ongoing to 
investigate the possible epidemiological association between this adverse event and vaccination with Pandemrix. 
Adjuvanted vaccines, such as Pandemrix, were licensed to use in children during the pandemic. Use of adjuvanted 
seasonal vaccines in children is very limited. At the time of the expert meeting and writing of the report, only 
limited evidence was yet available on the association between Pandemrix and narcolepsy.  
4.2 What is the best vaccination strategy to protect infants 
below the age of six months for whom there is no indication 
for influenza vaccination?  
a) Protecting the mother and her unborn child from serious illness: 
vaccinating pregnant women  
Evidence from systematic literature review  
No evidence was found in the systematic review, which was restricted to studies conducted in Europe.  
Additional literature provided by the experts  
Two papers on vaccination of pregnant women were provided by the experts52;53. The populations described in the 
papers are pregnant women from the general population without underlying morbidity. A randomised controlled 
trial was conducted in Bangladesh to assess the clinical effectiveness of maternal immunisation with inactivated 
influenza vaccine on influenza illness in infants and mothers. Among infants of mothers who received influenza 
vaccine, there were fewer cases of laboratory-confirmed influenza than among infants before 24 weeks of age in 
the control group (six and 16 cases, respectively), with a vaccine effectiveness of 63% (95% CI, 5 to 85). 
Respiratory illness with fever occurred in 110 infants in the influenza vaccine group and 153 infants in the control 
group, with a vaccine effectiveness of 29% (95% CI, 7 to 46)53.  
A non-randomised prospective observational cohort study was conducted in Navajo and White Mountain Apache 
Indian reservations (USA) to assess the effect of seasonal influenza vaccination during pregnancy on laboratory-
confirmed influenza in infants up to six months of age. A total of 1160 mother-infant pairs had serum collected and 
were included in the analysis. The ILI incidence rate was 7.2 and 6.7 per 1000 person-days for infants born to 
unvaccinated and vaccinated women, respectively. There was a 41% reduction in the risk of laboratory-confirmed 
influenza virus infection (relative risk, 0.59; 95% CI, 0.37 to 0.93) and a 39% reduction in the risk of ILI 
hospitalisation (relative risk 0.61; 95% CI, 0.45 to 0.84) for infants born to influenza-vaccinated women compared 
with infants born to unvaccinated mothers. Infants born to influenza-vaccinated women had significantly higher 
haemagglutinin inhibition antibody titers at birth and at two to three months of age than infants of unvaccinated 
mothers for all eight influenza virus strains investigated52.  
Further expert comments  
• If a woman is vaccinated during pregnancy, she is less likely to acquire influenza, which in turn reduces the 
chance of mother-to-child transmission after giving birth and during the first months of life. 
• The RCT conducted in Bangladesh showed that influenza antibodies from the mother are transferred to the 
child.  
• The use of antiviral therapy is not licensed in children younger than six months of age. The same applies to 
influenza vaccines. Therefore, there is a lack of alternatives to protect or treat children younger than six 
months against influenza, while the burden in this group is high.  
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• Although evidence from Europe is lacking, there is reassuring evidence from the US, where two million 
pregnant women were vaccinated against influenza between 2000 and 2003, and only 20 adverse events 
were reported to VAERSxiv. These included nine injection-site reactions and eight systemic reactions (e.g. 
fever, headache, and myalgias). In addition, three miscarriages were reported, but no causal relationship to 
vaccination54 has been established.  
b) Vaccination of contacts: evidence from the systematic literature 
review 
The systematic review found no evidence.  
Evidence from literature provided by the experts 
The experts provided no additional literature.  
Further expert comments  
• Vaccinating contacts of young children could help prevent transmission of the virus to the infant, but 
evidence is lacking.  
c) What are the main knowledge gaps and areas of uncertainty that 
require additional research? 
The main gaps are the following: 
• European data on vaccine-effectiveness in children are limited.  
• Large population studies to estimate the burden of influenza by age group have not been conducted in 
Europe so far. 
• Limited data are available from active post-licensing surveillance of severe adverse outcomes associated 
with seasonal influenza immunisation in Europe.  
d) The following is advised: 
• Case-based severe influenza surveillance for Europe should be strengthened and should cover more 
countries. Surveillance should include all age groups in order to allow comparisons between age groups and 
estimate burden by age. Surveillance data should include information about underlying medical conditions, 
clinical presentation/severity (lower respiratory tract infection), and clinical outcome. 
• In countries that recommend seasonal influenza vaccination in young children (e.g. the USA and Finland), 
coverage is rather low. There are a number of possible obstacles to seasonal influenza vaccination that 
need to be eliminated through targeted interventions and focused research investments.  
More evidence on the burden of disease in this age group and on the effectiveness of vaccination is needed 
to support parents’ decision on seasonal influenza vaccination of their children. Furthermore, annual 
revaccinations and the fact that two doses are needed for first-time vaccinees, are time-consuming and 
require an additional effort on the part of the parents. This is an important disincentive to increasing 
vaccination rates in children; supportive actions towards parents should be considered when attempting to 
increase vaccination coverage in children. If vaccination of young children is recommended, it is advisable 
to monitor the public opinion on vaccinating children against influenza and against other infections in order 
to improve strategies to increase or protect achieved vaccination coverage.  
• It is advisable that following the introduction of childhood vaccination programmes, population based post-
marketing surveillance should be established to monitor vaccine effectiveness, vaccine safety and the 
impact of vaccination.  
• Well-designed RCTs should be conducted to increase the available evidence on vaccine efficacy.  
  
 
                                                                    
xiv The US HHS and FDA Vaccine Adverse Event Reporting System; see http://vaers.hhs.gov/index. 
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5 Scientific advice: vaccination of pregnant 
women  
5.1 What is the evidence for and against influenza 
vaccination of all women who are pregnant during the 
periods of influenza circulation, regardless of the pregnancy 
trimester and the presence of co-morbidities?  
a) Burden of disease: evidence from systematic literature review 
The articles selected in the systemic review on burden of influenza in pregnant women are summarised in Annex 3 
(Tables 18 and 19).  
2009 pandemic 
Seventeen studies (six from European countries and 11 from other Western countries) exploring the burden of 
pandemic influenza A(H1N1) among pregnant women were included. None of the studies included only healthy 
pregnant women. Nine studies included pregnant women with underlying conditions. Two studies possibly included 
women with underlying conditions, and six studies did not elaborate on underlying conditions. 
Sixteen studies (five from European and 11 from other Western countries) relating to pandemic influenza A(H1N1) 
hospitalisations among pregnant women (Table 18) were selected; a further eleven studies on mortality (four from 
European and seven from other Western countries) were included (Table 19).  
Two studies (one from Ireland, one from the UK) showed that 4.3% (Ireland) and 6.7% (UK) of the hospitalised 
cases in the total study group of patients hospitalised for pandemic influenza A(H1N1) were pregnant2;4. A Greek 
and a French study that both investigated ICU admissions reported pregnancy rates at 4.4% (Greece) and 13% 
(France; 61% of the French cases had underlying conditions)1;55. In the Netherlands, 3.5% of non-ICU and 3.8% 
of ICU admissions with information available were pregnant women3. 
Pregnant women accounted for 5.8% to 13% of the hospitalisations in Australia and the US6;8;56-58; 7.2% to 19% 
of the ICU admissions were due to pandemic influenza in Australia and the US8;57-60. Most admissions were 
pregnant women in the second half or third trimester of pregnancy8;61-64, while in the UK Nguyen Van-Tam et al. 
reported that the majority of hospitalised pregnant women were in the second trimester of pregnancy2. In a study 
by Hegawama et al. in Australia, 51% of the pregnant women had underlying conditions62.  
In the Netherlands, none of the pregnant women hospitalised with confirmed influenza during the pandemic died3. 
Two studies reported the proportion of pregnant women among all deaths in hospitalised pandemic cases (France: 
2.7%, UK: 6.9%)1;2. One study from Greece measured the proportion of pregnant women among all deaths in ICU-
admitted pandemic cases (0.7%2;55). One study described the complete pandemic period (England) and found that 
the case fatality rate for pregnant women was 90 per 100 000 clinical cases16. In Australia and the US, the 
proportion of pregnant women among all deaths in pandemic hospitalised cases ranged from 1.6% 
to 16%6;8;56;58;59. The proportion of pregnant hospitalised influenza cases that died ranged from 1.1% 
to 16.7%6;8;56;58;63;64. One study presented mortality per trimester and found that most deaths among pregnant 
women occurred in the third trimester64.  
Seasonal influenza 
No European studies were found in the period of the literature review (articles published in 2000 and after). Two 
studies (both from the US) reported on outcomes of seasonal influenza in pregnancy65;66. In Shiley et al., a total of 
503 cases of seasonal influenza with complete records available for review were identified from 1 November 2005 
through 1 June 2008 in one hospital. Of these, 381 cases (76%) were diagnosed in hospitalised patients and 122 
(24%) during emergency department visits that did not lead to hospital admission. Seven cases were pregnant 
(1.4%). No pregnant women with seasonal influenza died or required ICU admission. The authors did not report 
the percentage of pregnant women with underlying conditions. In Rogers et al., 107 hospitalised pregnant women 
(16% with underlying conditions) diagnosed with influenza A were included (season 2003/04). Twelve per cent of 
these women developed pneumonia. There were no significant differences between the neonatal outcomes of 
these pregnant women with influenza A and the outcomes of the general obstetric population66.  
 
 
 
 
TECHNICAL REPORT ECDC scientific advice on seasonal influenza vaccination of children and pregnant women 
 
 
 
15 
 
 
 
Additional literature provided by the experts 
Mak et al. and Blanchard-Rohner and Siegrist reported the findings of systematic literature reviews which 
concluded that there was evidence of excess morbidity and mortality in pregnant women during seasonal and 
pandemic influenza67;68. 
In Canada, hospital admission records of women admitted from 1994 to 2000 with a respiratory condition during 
pregnancy were extracted from the hospitalisation database. Approximately 300 hospitalisations of pregnant 
women per year were attributed to influenza, of which 140 were in women with co-morbidities. This hospitalisation 
rate corresponds to 150 (95% CI, 140 to 170) hospitalisations per 100 000 pregnant women per year. An 
estimated one in 1000 healthy pregnant women were hospitalised due to influenza per year. Pre-existing asthma 
was the most important risk factor for hospitalisation in pregnant women, accounting for an estimated 450 (95% 
CI, 300 to 600) admissions per 100 000 pregnant women69. 
In another systematic review, Ortiz et al. found that the odds of hospitalisation for respiratory conditions increased 
by trimester (from OR 1.4 in the second trimester to OR 4.7 in the third trimester); otherwise healthy women in 
their third trimester had similar risks to non-pregnant women with chronic co-morbidity conditions70.  
Pierce et al. described the outcomes of pregnancy among a cohort of 272 women in the UK admitted to hospital 
with confirmed influenza during the second wave of pandemic infection between September 2009 and January 
2010. In this cohort, 14% of the women had asthma, and 20% had other co-morbidities than asthma. Perinatal 
mortality was higher in infants born to infected women (39 (95% CI, 19 to 71) per 1000 total births) than in 
infants of uninfected women (seven (3–13) per 1000 total births) (p<0.001). This was principally explained by an 
increase in the rate of stillbirth (27 per 1000 total births compared with six per 1000 total births; p=0.001). 
Infected women who delivered preterm were more likely to be infected in their third trimester (p=0.046), get 
admitted to an intensive care unit (p<0.001), and have a secondary pneumonia (p=0.001) than those who 
delivered at term71.   
Further expert comments  
• In Australia and New Zealand the number of hospitalisations of pregnant women during the pandemic was 
higher than would be expected based on population distribution (i.e. more than 1 to 1.5%). However, 
during the pandemic, pregnant women were possibly more closely watched than during seasonal influenza, 
which could have contributed to the higher proportion of hospitalisations in this group.  
• As indicated above, data on burden of disease in pregnant women attributable to seasonal influenza are 
scarce from European countries. This is partly because surveillance systems usually do not include pregnant 
women as a specific population during seasonal influenza; instead, they are included in the total population.   
b) Vaccine effectiveness: evidence from the systematic literature 
review 
No European studies published in 2000 and after could be retrieved that contained data on influenza vaccine 
effectiveness in pregnant women.  
Additional literature provided by the experts 
In their reviews, Mak et al. and Blanchard-Rohner and Siegrist surveyed the literature on influenza vaccination 
during pregnancy. Many of the included studies focused on the effect of the vaccine to protect young infants 
against influenza. The studies that used maternal outcomes after vaccination showed a reduction in confirmed 
influenza or respiratory illness with fever, other studies however failed to show a decreased risk67;68. Blanchard-
Rohner and Siegrist concluded that influenza vaccination during pregnancy reduced the maternal disease burden70, 
while Mak et al. concluded that more evidence was needed on the evaluation of the assumed benefits of 
vaccinating pregnant women71.  
Further expert comments  
• Based on immunogenicity studies there are no indications that vaccine effectiveness is different in pregnant 
women compared with the general adult population. Although there are immune system adaptations during 
pregnancy which are responsible for the higher burden of influenza disease, it is unclear whether these 
have an influence on vaccine effectiveness.  
• Data from the Netherlands indicate that an estimated 1500 healthy pregnant women would need to be 
vaccinated in order to prevent one hospital admission in this group due to seasonal influenzaxv.  
 
                                                                    
xv Health Council of the Netherlands. Vaccination of pregnant women against seasonal influenza 2010–2011. Health Council of the 
Netherlands: The Hague; 2010. Available from: http://www.gezondheidsraad.nl/sites/default/files/201014.pdf 
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c) Vaccine safety: evidence from the systematic literature review 
No European studies published in 2000 and after were retrieved that contained data on influenza vaccine safety in 
pregnant women.  
Additional literature provided by the experts 
Tamma et al. conducted a review on safety of influenza vaccination during pregnancy and concluded that the lack 
of harmful effects of inactivated influenza vaccination on maternal health during pregnancy has been demonstrated 
in several studies (two RCTs and 10 observational studies)72. These studies were non-European studies and/or 
were published before 2000.  
Mak et al. concluded in their review that research on vaccine safety in pregnant women is limited. The few 
prospective studies of pregnant women suggest that the vaccine is safe71. Blanchard-Rohner and Siegrist included 
ten studies on safety of influenza immunisation during pregnancy. No serious adverse events or increase in 
adverse pregnancy outcomes were shown in any of these studies70. 
No serious adverse effects of influenza immunisation in pregnancy have been reported in the few published studies 
on vaccine safety. This evidence is from non-European studies, and data on burden are from before the year 2000. 
Although evidence from Europe is lacking, there is reassuring evidence from the US, where two million pregnant 
women were vaccinated against influenza between 2000 and 2003, and only 20 adverse events were reported to 
the VAERS system. These included nine injection-site reactions and eight systemic reactions (e.g. fever, headache, 
and myalgias). In addition, three miscarriages were reported, but no causal relationship to vaccination has been 
established54.  
Further expert comments  
• At the moment, there are no indications that vaccinating pregnant women causes harm. 
• However, data are on safety are scarce, especially for Europe, since there is no published information on 
RCTs or large observational studies in Europe.  
• If a country should decide to recommend the vaccination of healthy pregnant women, there are some 
operational issues to consider. Two suggestions were pointed out by the experts: 
− In countries where nearly everyone is registered with a general practitioner (GP), personal 
invitations by the GP could be an option. The prerequisite for this is that the GP is informed when his 
or her patients are pregnant.   
− Another option to reach pregnant women is through the midwifery and obstetricians/gynaecologists. 
In most European countries, pregnant women will visit one of these specialists during their 
pregnancy.  
d) What are the main knowledge gaps and areas of uncertainty that 
require additional research? 
The following main gaps were identified: 
• Data from Europe on burden of seasonal influenza in pregnant women (either healthy women or those with 
underlying conditions).  
• Data from Europe on vaccine effectiveness and safety in pregnant women (either healthy women or those 
with underlying conditions).  
e) The following is advised: 
• Severe influenza surveillance systems should include pregnant women as a specific category to gain more 
insight into the burden of influenza in pregnant women. These data should cover all European countries. An 
alternative approach would be to conduct large multicentre cohort studies which follow up on pregnant 
women during the influenza seasons and record influenza-related outcomes. 
• Hospitalisations and ICU admissions should be added as outcomes in existing surveillance systems or cohort 
studies, next to mortality. Data on hospitalisations could serve as a marker for differences in influenza 
outcomes due to differences in healthcare systems.  
• Safety studies of women vaccinated with the seasonal influenza vaccine during pregnancy should be 
conducted in Europe.  
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6 Additional information 
Limitations 
The evidence for this advisory report was collected using two different methods, a systematic literature review and 
literature referrals to additional literature identified by a panel of experts.  
The literature search for the systematic part of the review was limited to publications released from 2000 to July 
2010. The additional literature provided by the experts proved particularly useful as it allowed the inclusion of 
relevant evidence that would have otherwise been omitted because of the temporal restrictions of the systematic 
review. Furthermore, the vaccine-related topics were limited to articles based on European data. Again, the 
additional literature proved particularly valuable as it provided a broader perspective to the advice formulated here. 
Unlike the studies included in the systematic review, the literature provided by the experts was neither 
systematically selected nor critically appraised. Therefore data from these papers are not included in the evidence 
tables in Annex 2. More evidence on the topics described in this document was becoming available at the time this 
report was written. Therefore some of the gaps identified here may become less relevant.  
Next steps by ECDC 
The scientific advice contained in this document will be disseminated by ECDC through the European Commission’s 
Directorate General for Health and Consumers (SANCO), the Health Security Committee’s Influenza Section, the 
ECDC Advisory Forum, the ECDC Vaccine Advisory Group (EVAG); it will also be published on the ECDC website. 
ECDC monitors influenza vaccine coverage in EU on a routine basis through annual surveys run by the VENICE 
collaboration (http://venice.cineca.org/). Such surveys include information on the groups for whom vaccination is 
recommended by national authorities (if collected) and will serve as a tool to monitor the implementation of the 
advice contained in this document.  
Further updates 
The systematic part of the review will be updated in two years’ time (2014). In the meantime, the ECDC influenza 
programme will continue to monitor scientific data, analyses and publications and make its findings available 
through the ECDC Scientific Advances and Public Health Developments series.  
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Annex 1. Systematic review of scientific 
literature 
The search strategies used for this publication were developed by Pallas health research and consultancy. The 
initial selection was based on title and abstracts. Pallas critically appraised full-text articles based on CoCanCPG 
checklists and then summarised the evidence.  
Pallas conducted a search using the search strategies as described below. PubMed search strings were used to 
identify the amount of articles that needed to be processed during the project. The search strategy was approved 
by ECDC. PubMed was the core database for the review. Since Embase contains more European journals and 
pharmacological journals than PubMed, Embase was particularly useful for Aim 3 (see Section 3 above: ‘Systematic 
review’). Embase was also searched for articles on burden of influenza in pregnancy in order to retrieve additional 
articles since literature on this subject is scarce.  
PubMed 
Search strategy 1 for influenza 
The search string below was used to identify the disease by using medical subject headings [MeSH] and text words 
[tw]. By using general influenza text words, such as influenza, flu, influenza-like illness and flu-like illness, all 
subtypes of influenza were supposed to be covered. We added some extra terms for the new pandemic influenza 
A(H1N1).  
(Human influenza [MeSH] OR Influenza A Virus, H1N1 Subtype[MeSH] OR influenza[tw] OR flu[tw] OR influenza-
like illness[tw] OR flu-like illness[tw] OR swine flu[tw] OR swine origin influenza[tw] OR 2009 pandemic[tw] OR 
2009 pandemic influenza[tw] OR AH1N1v[tw] OR 2009 H1N1[tw]) 
Search strategy 2 geographical scope 
The search for the disease was combined with a search string for European countries.  
We selected the articles included in the geographical scope of the review by searching for country names as text 
words (tag [tw]) or country names in the author’s affiliation (tag [ad]).  
Therefore the following search string was used for European countries (2a): 
(Europe[MeSH] OR Europe*[tw] OR Andorr*[tw] OR Austria*[tw] OR Belgi*[tw] OR Albania*[tw] OR Baltic*[tw] 
OR Estoni*[tw] OR Latvi*[tw] OR Lithuani*[tw] OR Bosni*[tw] OR Herzegovin*[tw] OR Bulgari*[tw] OR 
Byelarus*[tw] OR Croatia*[tw] OR Czech*[tw] OR Hungar*[tw] OR Macedonia*[tw] OR Moldov*[tw] OR 
Montenegr*[tw] OR Poland*[tw] OR Polish*[tw] OR Romania*[tw] OR Russia*[tw] OR Bashkiri*[tw] OR 
Dagestan*[tw] OR Serbia*[tw] OR Slovaki*[tw] OR Sloveni*[tw] OR Ukrain*[tw] OR Yugoslavi*[tw] OR 
Finland*[tw] OR Finnish*[tw] OR France*[tw] OR French*[tw] OR German*[tw] OR Gibraltar*[tw] OR Great 
Britain*[tw] OR Brittish*[tw] OR British*[tw] OR Channel Islands*[tw] OR Guerns*[tw] OR England*[tw] OR 
English*[tw] OR Hebrid*[tw] OR Ireland*[tw] OR Irish*[tw] OR Scotland*[tw] OR Scotch*[tw] OR Scottish*[tw] 
OR Wales*[tw] OR Welsh*[tw] OR Greec*[tw] OR Greek*[tw] OR Iceland*[tw] OR Ital*[tw] OR Sicil*[tw] OR 
Liechtenstein*[tw] OR Luxembourg*[tw] OR Mediterranean Region*[tw] OR Mediterranean Islands*[tw] OR 
Cyprus*[tw] OR Cipriot*[tw] OR Malta*[tw] OR Monaco*[tw] OR Monas*[tw] OR Netherland*[tw] OR Dutch*[tw] 
OR Portugal*[tw] OR Portuges*[tw] OR San Marin*[tw] OR Scandinavia*[tw] OR Denmark*[tw] OR Danish*[tw] 
OR Norwa*[tw] OR Svalbard*[tw] OR Sweden*[tw] OR Swedish*[tw] OR Spain*[tw] OR Spanish*[tw] OR 
Switzerland*[tw] OR Swiss*[tw] OR Transcaucasia*[tw] OR Armenia*[tw] OR Azerbaijan*[tw] OR Georgia*[tw] 
OR Vatican*[tw] OR Europe*[ad] OR Andorr*[ad] OR Austria*[ad] OR Belgi*[ad] OR Albania*[ad] OR Baltic*[ad] 
OR Estoni*[ad] OR Latvi*[ad] OR Lithuani*[ad] OR Bosni*[ad] OR Herzegovin*[ad] OR Bulgari*[ad] OR 
Byelarus*[ad] OR Croatia*[ad] OR Czech*[ad] OR Hungar*[ad] OR Macedonia*[ad] OR Moldov*[ad] OR 
Montenegr*[ad] OR Poland*[ad] OR Polish*[ad] OR Romania*[ad] OR Russia*[ad] OR Bashkiri*[ad] OR 
Dagestan*[ad] OR Serbia*[ad] OR Slovaki*[ad] OR Sloveni*[ad] OR Ukrain*[ad] OR Yugoslavi*[ad] OR 
Finland*[ad] OR Finnish*[ad] OR France*[ad] OR French*[ad] OR German*[ad] OR Gibraltar*[ad] OR Great 
Britain*[ad] OR Brittish*[ad] OR British*[ad] OR Channel Islands*[ad] OR Guerns*[ad] OR England*[ad] OR 
English*[ad] OR Hebrid*[ad] OR Ireland*[ad] OR Irish*[ad] OR Scotland*[ad] OR Scottish*[ad] OR Scotch*[ad] 
OR Wales*[ad] OR Welsh*[ad] OR Greec*[ad] OR Greek*[ad] OR Iceland*[ad] OR Ital*[ad] OR Sicil*[ad] OR 
Liechtenstein*[ad] OR Luxembourg*[ad] OR Mediterranean Region*[ad] OR Mediterranean Islands*[ad] OR 
Cyprus*[ad] OR Cipriot*[ad] OR Malta*[ad] OR Monaco*[ad] OR Monas*[ad] OR Netherland*[ad] OR Dutch*[ad] 
OR Portugal*[ad] OR Portuges*[ad] OR San Marin*[ad] OR Scandinavia*[ad] OR Denmark*[ad] OR Danish*[ad] 
OR Norwa*[ad] OR Svalbard*[ad] OR Sweden*[ad] OR Swedish*[ad] OR Spain*[ad] OR Spanish*[ad] OR 
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Switzerland*[ad] OR Swiss*[ad] OR Transcaucasia*[ad] OR Armenia*[ad] OR Azerbaijan*[ad] OR Georgia*[ad] 
OR Vatican*[ad])  
For the review Aims 1 and 2 the geographical scope was extended outside Europe focusing on the United States, 
Canada, Australia, New Zealand, and Japan, in order to provide all relevant articles on burden of influenza in 
children and pregnant women. The above-mentioned search string (2a) was extended to (2b):  
(“United States”[tw] OR US[tw] OR U.S.A.[tw] OR America*[tw] OR Canad*[tw] OR Austral*[tw] OR New 
Zealand*[tw] OR Japan*[tw] OR America*[ad] OR "United States"[ad] OR US[ad] OR U.S.A.[ad] OR Canad*[ad] 
OR Austral*[ad] OR New Zealand*[ad] OR Japan*[ad]) 
Search strategy 3 for Aim 1: burden of influenza 
To identify scientific articles on burden of influenza, we used the search string below, which was combined with 
the search string for the disease (1) and the geographical scope limited to Europe, the United States, Canada, and 
Australia (2a and 2b).  
(epidemiology[MeSH] OR epidemiology[subheading] OR epidemiology[tw] OR incidence*[tw] OR morbidity*[tw] 
OR mortality[tw] OR mortality[subheading] OR death*[tw] OR “case-fatality”[tw] OR lethal*[tw] OR hospital*[tw] 
OR “hospital admission*”[tw] OR visit*[tw] OR complication*[tw] OR pneumonia[tw] OR respiratory disease*[tw] 
OR respiratory complication*[tw] OR respiratory disorder*[tw] OR respiratory tract infection*[tw] OR chronic 
disease*[tw] OR chronic disorder*[tw] OR chronic medical condition*[tw] OR asthma exacerbation*[tw] OR 
asthma[tw] OR diabetes*[tw] OR heart disease*[tw] OR heart disorder*[tw] OR heart failure[tw] OR otitis 
media[tw] OR ear infection*[tw] OR sinusitis[tw] OR bronchiolitis[tw] OR croup[tw] OR dehydration[tw] OR 
myositis[tw] OR fetal loss[tw] OR foetal loss[tw] OR fetal death[tw] OR spontaneous abortion OR miscarriage[tw] 
OR pregnancy termin*[tw]) 
Search strategy 4 for Aim 2: burden of influenza in young children 
when contacts are vaccinated 
To identify scientific articles on burden of influenza in young children (i.e. between 0 and 59 months old) with 
vaccinated contacts we used the search string below, which was combined with the search string for disease (1), 
the geographical scope limited to Europe, the United States, Canada, and Australia (2a and 2b), and the search 
string for burden of influenza (3).  
((Health personnel[MeSH] OR Household contacts[tw] OR caregivers[MeSH] OR caregiver*[tw] OR caretaker[tw] 
OR nurses[MeSH] OR nurse*[tw] OR physicians[MeSH] OR physician*[tw] OR health care staff[tw] OR carer*[tw] 
OR healthcare personnel[tw] OR "Disease Transmission, Infectious"[Mesh] OR "Infectious Disease Transmission, 
Professional-to-Patient"[Mesh] OR family transmission[tw] OR household transmission[tw] OR famil*[tw]) AND 
(child*[tw] OR infan*[tw] OR pediatr*[tw] OR paediatr*[tw]) AND ("influenza vaccines"[MeSH] OR vaccination[tw] 
OR vaccin*[tw] OR immunisation[tw] OR immunisation[tw] OR immunogen*[tw] OR immunity*[tw])))  
Search strategy 5 for Aim 3: vaccine safety, effectiveness, and cost 
effectiveness 
To identify scientific articles on issues related to vaccine safety, effectiveness, and cost effectiveness of vaccination, 
we used the search string below, which was combined with the search string for the disease (1) and the 
geographical scope limited to Europe (2a).  
(“influenza vaccines”[MeSH] OR vaccination[tw] OR vaccin*[tw] OR immunisation[tw] OR immunisation[tw] OR 
immunogen*[tw] OR immunity*[tw]) AND (outbreak[tw] OR effectiv*[tw] OR efficacy[tw] OR “cost of 
illness”[MeSH] OR “attack rate”[tw] OR protection[tw] OR safety[tw] OR AEFI[tw] OR (adverse event[tw] AND 
immunisation[tw]) OR (adverse event[tw] AND immunisation[tw]) OR neuritis[tw] OR convulsion[tw] OR 
anaphylaxis[tw] OR encephalitis[tw] OR vasculitis[tw] OR Guillain-Barre syndrome[tw] OR Bell’s palsy[tw] OR Bell 
palsy[tw] OR Bells palsy[tw] OR demyelinating diseas*[tw] OR demyelinating disor*[tw]) 
Search strategy 6 for population 
To identify scientific articles for the population-specific data for year 1 (2010), we used two additional search 
strategies (see below) that were combined with the search strings 1, 2, 3 and 5.  
Search strategy for children aged 6 to 59 months and 5 to 18 years 
To identify scientific articles about children (6 months to 18 years), we used the following search string (6a):  
(child*[tw] OR infan*[tw] OR adolescen*[tw] OR pediatr*[tw] OR paediatr*[tw] OR juven*[tw]) 
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Search strategy for pregnant women 
To identify scientific articles about women who will be or are pregnant during influenza season, we used the 
following search string (6b):  
(Pregnancy[MeSH] OR pregnancy[tw] OR pregnant women[MeSH] OR pregnant women[tw] OR ‘Pregnancy 
Complications, Infectious/prevention and control’[MAJR] OR preconception care[MeSH] OR preconception[tw] OR 
pregnancy intention[tw]) 
Limits 
We used the following limits:  
• NOT (case study OR case studies OR case report*) 
• Publication date: last ten years 
• Languages: English, French, German, Italian, Spanish, Dutch 
Embase 
Search strategy 1: influenza 
The following search strategy was used to identify the disease, using Emtree terms (/exp) and abstract (:ab): 
('influenza virus'/exp OR 'swine influenza virus'/exp OR 'influenza virus a'/exp OR 'influenza virus a h1n1'/exp 
OR influenza:ab OR flu:ab OR 'influenza-like illness':ab OR 'flu-like illness':ab OR 'swine flu':ab OR 'swine origin 
influenza':ab OR '2009 pandemic':ab OR '2009 pandemic influenza':ab OR 'ah1n1v':ab OR '2009 h1n1':ab 
OR influenza:ti OR flu:ti OR 'influenza-like illness':ti OR 'flu-like illness':ti OR 'swine flu':ti OR 'swine origin 
influenza':ti OR '2009 pandemic':ti OR '2009 pandemic influenza':ti OR 'ah1n1v':ti OR '2009 h1n1':ti) 
Search strategy 2: geographical scope 
The search for the disease was combined with a search string for European countries.  
We selected the articles included in the geographical scope of the review by searching for the country names as 
abstract (tag ‘:ab’), title (tag ‘:ti’) or the country names in the author’s affiliation (tag ‘:ad’).  
Therefore the following search string was used for European countries (2a): 
(Europe*:ab OR Andorr*:ab OR Austria*:ab OR Belgi*:ab OR Albania*:ab OR Baltic*:ab OR Estoni*:ab OR 
Latvi*:ab OR Lithuani*:ab OR Bosni*:ab OR Herzegovin*:ab OR Bulgari*:ab OR Byelarus*:ab OR Croatia*:ab OR 
Czech*:ab OR Hungar*:ab OR Macedonia*:ab OR Moldov*:ab OR Montenegr*:ab OR Poland*:ab OR Polish*:ab 
OR Romania*:ab OR Russia*:ab OR Bashkiri*:ab OR Dagestan*:ab OR Serbia*:ab OR Slovaki*:ab OR Sloveni*:ab 
OR Ukrain*:ab OR Yugoslavi*:ab OR Finland*:ab OR Finnish*:ab OR France*:ab OR French*:ab OR German*:ab 
OR Gibraltar*:ab OR (Great:ab AND Britain*:ab) OR Brittish*:ab OR British*:ab OR (Channel:ab AND Islands*:ab) 
OR Guerns*:ab OR England*:ab OR English*:ab OR Hebrid*:ab OR Ireland*:ab OR Irish*:ab OR Scotland*:ab OR 
Scotch*:ab OR Scottish*:ab OR Wales*:ab OR Welsh*:ab OR Greec*:ab OR Greek*:ab OR Iceland*:ab OR Ital*:ab 
OR Sicil*:ab OR Liechtenstein*:ab OR Luxembourg*:ab OR (Mediterranean:ab AND Region*:ab) OR 
(Mediterranean:ab AND Islands*:ab) OR Cyprus*:ab OR Cipriot*:ab OR Malta*:ab OR Monaco*:ab OR Monas*:ab 
OR Netherland*:ab OR Dutch*:ab OR Portugal*:ab OR Portuges*:ab OR (San:ab AND Marin*:ab) OR 
Scandinavia*:ab OR Denmark*:ab OR Danish*:ab OR Norwa*:ab OR Svalbard*:ab OR Sweden*:ab OR 
Swedish*:ab OR Spain*:ab OR Spanish*:ab OR Switzerland*:ab OR Swiss*:ab OR Transcaucasia*:ab OR 
Armenia*:ab OR Azerbaijan*:ab OR Georgia*:ab OR Vatican*:ab OR Europe*:ad OR Andorr*:ad OR Austria*:ad 
OR Belgi*:ad OR Albania*:ad OR Baltic*:ad OR Estoni*:ad OR Latvi*:ad OR Lithuani*:ad OR Bosni*:ad OR 
Herzegovin*:ad OR Bulgari*:ad OR Byelarus*:ad OR Croatia*:ad OR Czech*:ad OR Hungar*:ad OR Macedonia*:ad 
OR Moldov*:ad OR Montenegr*:ad OR Poland*:ad OR Polish*:ad OR Romania*:ad OR Russia*:ad OR Bashkiri*:ad 
OR Dagestan*:ad OR Serbia*:ad OR Slovaki*:ad OR Sloveni*:ad OR Ukrain*:ad OR Yugoslavi*:ad OR Finland*:ad 
OR Finnish*:ad OR France*:ad OR French*:ad OR German*:ad OR Gibraltar*:ad OR (Great:ad AND Britain*:ad) 
OR Brittish*:ad OR British*:ad OR (Channel:ad AND Islands*:ad) OR Guerns*:ad OR England*:ad OR English*:ad 
OR Hebrid*:ad OR Ireland*:ad OR Irish*:ad OR Scotland*:ad OR Scottish*:ad OR Scotch*:ad OR Wales*:ad OR 
Welsh*:ad OR Greec*:ad OR Greek*:ad OR Iceland*:ad OR Ital*:ad OR Sicil*:ad OR Liechtenstein*:ad OR 
Luxembourg*:ad OR (Mediterranean:ad AND Region*:ad) OR (Mediterranean:ad AND Islands*:ad) OR Cyprus*:ad 
OR Cipriot*:ad OR Malta*:ad OR Monaco*:ad OR Monas*:ad OR Netherland*:ad OR Dutch*:ad OR Portugal*:ad 
OR Portuges*:ad OR (San:ad AND Marin*:ad) OR Scandinavia*:ad OR Denmark*:ad OR Danish*:ad OR Norwa*:ad 
OR Svalbard*:ad OR Sweden*:ad OR Swedish*:ad OR Spain*:ad OR Spanish*:ad OR Switzerland*:ad OR 
Swiss*:ad OR Transcaucasia*:ad OR Armenia*:ad OR Azerbaijan*:ad OR Georgia*:ad OR Vatican*:ad OR 
Europe*:ti OR Andorr*:ti OR Austria*:ti OR Belgi*:ti OR Albania*:ti OR Baltic*:ti OR Estoni*:ti OR Latvi*:ti OR 
Lithuani*:ti OR Bosni*:ti OR Herzegovin*:ti OR Bulgari*:ti OR Byelarus*:ti OR Croatia*:ti OR Czech*:ti OR 
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Hungar*:ti OR Macedonia*:ti OR Moldov*:ti OR Montenegr*:ti OR Poland*:ti OR Polish*:ti OR Romania*:ti OR 
Russia*:ti OR Bashkiri*:ti OR Dagestan*:ti OR Serbia*:ti OR Slovaki*:ti OR Sloveni*:ti OR Ukrain*:ti OR 
Yugoslavi*:ti OR Finland*:ti OR Finnish*:ti OR France*:ti OR French*:ti OR German*:ti OR Gibraltar*:ti OR 
(Great:ti AND Britain*:ti) OR Brittish*:ti OR British*:ti OR (Channel:ti AND Islands*:ti) OR Guerns*:ti OR 
England*:ti OR English*:ti OR Hebrid*:ti OR Ireland*:ti OR Irish*:ti OR Scotland*:ti OR Scottish*:ti OR Scotch*:ti 
OR Wales*:ti OR Welsh*:ti OR Greec*:ti OR Greek*:ti OR Iceland*:ti OR Ital*:ti OR Sicil*:ti OR Liechtenstein*:ti 
OR Luxembourg*:ti OR (Mediterranean:ti AND Region*:ti) OR (Mediterranean:ti AND Islands*:ti) OR Cyprus*:ti OR 
Cipriot*:ti OR Malta*:ti OR Monaco*:ti OR Monas*:ti OR Netherland*:ti OR Dutch*:ti OR Portugal*:ti OR 
Portuges*:ti OR (San:ti AND Marin*:ti) OR Scandinavia*:ti OR Denmark*:ti OR Danish*:ti OR Norwa*:ti OR 
Svalbard*:ti OR Sweden*:ti OR Swedish*:ti OR Spain*:ti OR Spanish*:ti OR Switzerland*:ti OR Swiss*:ti OR 
Transcaucasia*:ti OR Armenia*:ti OR Azerbaijan*:ti OR Georgia*:ti OR Vatican*:ti)  
For the literature on burden of influenza in pregnancy, the geographical scope was extended outside Europe, 
focusing on the United States, Canada, Australia, New Zealand and Japan to retrieve all relevant articles. The 
above-mentioned search string (2a) was extended to (2b):  
(US*:ab OR (United:ab AND States*:ab) OR USA*:ab OR America*:ab OR Canad*:ab OR Austral*:ab OR (New:ab 
AND Zealand*:ab) OR Japan*:ab OR (United:ad AND States*:ad) OR US*:ad OR USA*:ab or America*:ab OR 
Canad*:ab OR Austral*:ad OR (New:ad AND Zealand*:ad) OR Japan*:ad OR (United:ti AND States:ti) OR US*:ti 
OR USA*:ti OR America*:ti OR Canad*:ti OR Austral*:ti OR (New:ti AND Zealand*:ti) OR Japan*:ti) 
Search strategy 3 for Aim 3: vaccine safety, effectiveness, and cost 
effectiveness 
To identify scientific papers on issues related to vaccine safety, effectiveness, and cost effectiveness of vaccination, 
we used the search string below, which was combined with the search string for the disease (1) and the 
geographical scope limited to Europe (2). This limit was set because not all vaccines available in the US are 
available in Europe (for which the advice in vaccination will be)  
'influenza vaccine'/exp OR 'swine influenza vaccine'/exp OR vaccination:ab OR vaccin*:ab OR immunisation:ab OR 
immunisation:ab OR immunogen*:ab OR immunity*:ab OR vaccination:ti OR vaccin*:ti OR immunisation:ti OR 
immunisation:ti OR immunogen*:ti OR immunity*:ti AND (outbreak:ab OR effectiv*:ab OR efficacy:ab OR 'attack 
rate':ab OR protection:ab OR safety:ab OR aefi:ab OR ('adverse event':ab AND immunisation:ab) OR ('adverse 
event':ab AND immunisation:ab) OR neuritis:ab OR convulsion:ab OR anaphylaxis:ab OR encephalitis:ab OR 
vasculitis:ab OR 'guillain-barre syndrome':ab OR 'bell palsy':ab OR 'bells palsy':ab OR outbreak:ti OR effectiv*:ti OR 
efficacy:ti OR 'cost of illness'/exp OR 'attack rate':ti OR protection:ti OR safety:ti OR aefi:ti OR ('adverse event':ti 
AND immunisation:ti) OR ('adverse event':ti AND immunisation:ti) OR neuritis:ti OR convulsion:ti OR anaphylaxis:ti 
OR encephalitis:ti OR vasculitis:ti OR 'guillain-barre syndrome':ti OR 'bell palsy':ti OR 'bells palsy':ti OR 
(demyelin*:ab AND diseas*:ab) OR (demyelin*:ab AND disor*:ab)) 
Search strategy 4: burden 
(‘epidemiology’/exp OR epidemiology:ab OR incidence:ab OR morbidity:ab OR mortality:ab OR death*:ab OR ‘case 
fatality’:ab OR lethal:ab OR hospital*:ab OR ‘hospital admission’:ab OR visit*:ab OR complication*:ab OR 
pneumonia:ab OR ‘respiratory disease’:ab OR ‘respiratory complication’:ab OR ‘respiratory disorder’:ab OR 
‘respiratory tract infection’:ab OR ‘chronic disease’:ab OR ‘chronic disorder’:ab OR ‘chronic medical condition’:ab OR 
‘asthma exacerbation’:ab OR asthma:ab OR diabetes:ab OR ‘heart disease’:ab OR ‘heart disorder’:ab OR ‘heart 
failure’:ab OR ‘otitis media’:ab OR ‘ear infection’:ab OR sinusitis:ab OR bronchiolitis:ab OR croup:ab OR 
dehydration:ab OR myositis:ab OR ‘fetal loss’:ab OR ‘foetal loss’:ab OR ‘fetal death’:ab OR ‘spontaneous 
abortion’:ab OR miscarriage*:ab OR (pregnancy:ab OR termin*:ab) OR epidemiology:ti OR incidence:ti OR 
morbidity:ti OR mortality:ti OR death*:ti OR ‘case fatality’:ti OR lethal:ti OR hospital*:ti OR ‘hospital admission’:ti 
OR visit*:ti OR complication*:ti OR pneumonia:ti OR ‘respiratory disease’:ti OR ‘respiratory complication’:ti OR 
‘respiratory disorder’:ti OR ‘respiratory tract infection’:ti OR ‘chronic disease’:ti OR ‘chronic disorder’:ti OR ‘chronic 
medical condition’:ti OR ‘asthma exacerbation’:ti OR asthma:ti OR diabetes:ti OR ‘heart disease’:ti OR ‘heart 
disorder’:ti OR ‘heart failure’:ti OR ‘otitis media’:ti OR ‘ear infection’:ti OR sinusitis:ti OR bronchiolitis:ti OR croup:ti 
OR dehydration:ti OR myositis:ti OR ‘fetal loss’:ti OR ‘foetal loss’:ti OR ‘fetal death’:ti OR ‘spontaneous abortion’:ti 
OR miscarriage*:ti OR (pregnancy:ti OR termin*:ti)) 
Search strategy 5 for population  
To identify scientific papers for the population-specific data for year 1 (2010), we used two additional search 
strategies (see below) that were combined with the search strings 1 to 4.  
Search strategy for children aged 6 to 59 months and 5 to 18 years 
To identify scientific papers about children (6 months to 18 years), we used the following search string (4a):  
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(child*:ab OR infan*:ab OR adolescen*:ab OR pediatr*:ab OR paediatr*:ab OR juven*:ab OR child*:ti OR infan*:ti 
OR adolescen*:ti OR pediatr*:ti OR paediatr*:ti OR juven*:ti) 
Search strategy for pregnant women 
To identify scientific papers about women who will be or are pregnant during influenza season, we used the 
following search string (4b):  
(‘pregnancy’/exp OR pregnancy:ab OR ‘pregnant women’:ab OR ‘Pregnancy Complication’/exp OR ‘maternal 
care’/exp OR preconception:ab OR ‘pregnancy intention’:ab OR pregnancy:ti OR ‘pregnant women’:ti OR 
preconception:ti OR ‘pregnancy intention’:ti) 
Limits 
We used the following limits:  
• NOT (case study OR case studies OR case report*) 
• Publication date: last ten years 
• Languages: English, French, German, Italian, Spanish, Dutch 
Key authors 
As suggested by ECDC, Pallas did an additional PubMed search on the following authors’ names: 
• “Fiore AE”[author] 
• “Jamieson DJ”[author] 
• “Neuzil KM”[author]  
We used the following limits: 
• NOT (case study OR case studies OR case report*) 
• Publication date: last ten years 
• Languages: English, French, German, Italian, Spanish, Dutch 
Hand search 
Through hand search (i.e. checking the references of the selected articles for additional relevant articles) Pallas 
updated key references possibly missed by the search in PubMed and Embase. This was done while completing the 
evidence tables.  
Other data sources 
Pallas browsed the following internet sites to identify data relevant to the aims of this review, particularly when 
data were scarce or not found in the literature: 
• European Medicine Agency, www.emea.europa.eu 
• ESWI (European Scientific Working group on Influenza), www.eswi.org  
• European Centre of Disease Prevention and Control, www.ecdc.europa.eu  
• European Influenza Surveillance Network (EISN) 
http://www.ecdc.europa.eu/en/activities/surveillance/EISN/Pages/home.aspx (formerly the European 
Influenza Surveillance Scheme (EISS))  
• Euvac, www.euvac.net 
• EuroFlu (WHO/Europe Influenza Surveillance), http://www.euroflu.org/index.php 
• Google (www.google.com), with a search on country name + ‘Influenza’ + if necessary, key words from the 
review objectives such as ‘surveillance’, ‘mortality’, ‘morbidity’. 
• Local national institutes of public health or ministries of health of the countries where the Google search did 
not lead to relevant institutes or data.  
• Librabry of ECDC’s influenza team 
Selection procedure and critical appraisal 
Pallas used a three-step selection procedure.  
1. First selection step: title and abstract 
In selection step 1, all articles retrieved from the search strategies were assessed. Two researchers executed this 
selection step independently.  
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The major topics of the articles were assessed by the title and abstract. Articles that did not contain information 
relevant to the research objectives, in abstract or title, were no selected for full text assessment.  
Examples for exclusion were: articles on treatment, animal study, other disease/infection than influenza was topic 
of article, phase II trial, vaccination coverage, attitude against vaccination, risk perception, study population other 
than defined in aims, acceptability of vaccination, simulation studies, travel-related pandemic H1N1 cases, case-
report, letter to the editor, expert’s opinion, and other countries than selected in search strategy.  
In a few cases it was doubtful whether the article should be included or excluded. These articles were included and 
moved to the second selection step.  
If an abstract was not available, and the title of that paper suggested that it could be relevant, the paper was 
selected for the second step.  
2. Second selection step: full article  
In this step the full text articles, selected in step 1, were assessed. Reasons for exclusion in this step were: 
• no relevant information (not possible to determine in selection step 1);  
• data on influenza were not presented separately, but in combination with, for example, pneumonia or RSV, 
or not further specified (e.g. respiratory illness);  
• poor quality. The Pallas team critically appraised the methodological quality of the articles using the 
CoCanCPG checklists (see Appendix 1). The CoCanCPG checklist was chosen because Pallas has experience 
with this checklist, and it is freely available. This choice was approved by ECDC. To the best of our 
knowledge, checklists for the critical appraisal of surveillance studies are not available. Appendix II 
describes the criteria we used to critically appraise surveillance studies. These criteria were based on the 
criteria for cohort studies, completed with a few other criteria applicable for the purpose of this review. If 
an article was of poor quality, the article was excluded. Criteria of poor quality were:  
− review or meta-analysis which lacks a description of the methodology, or the search is not 
sufficiently rigorous to identify all relevant articles; 
− randomised controlled trial in which the randomisation process is not described or not well executed, 
which could lead to bias; 
− surveillance study in which the source population is not well defined; 
• data on burden or vaccination that are older than the year 2000; 
• 75% or more of the children/pregnant women had underlying disease, and data were not separately 
presented for healthy cases vs. cases with underlying disease; 
• if a review on vaccination was of good quality, but contained mainly non-European studies, the review was 
excluded; European studies included in this review were retrieved and critically appraised.   
In Appendix 3 the exclusion table for selection step 2 is given. For each article excluded in the second step, a brief 
statement is provided on the main reason for exclusion. This way the selection procedure is transparent and 
ensures reproducibility. The exclusion table provides a tool for ECDC to evaluate the selection procedure.  
Articles that were not excluded in this step were selected for inclusion in the evidence tables (Annex 3).  
3. Third selection step: full article for production of evidence tables 
While producing the evidence tables, some additional papers were excluded and added to the exclusion table. This 
includes articles that only described the first few months of the pandemic while more complete papers for the 
same country were available, a number of fewer than 100 hospitalised cases in pandemic studies, results from only 
one school or hospital while larger population data were available, articles retrieved from review studies that were 
of poor quality.  
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Annex 2. Reasons for exclusion  
PubMed and hand search 
1 Acs 2005 The content of this article does not provide data that meet the objectives 
2 Ajayi-Obe 2008 This article does not describe results for the population of interest 
3 Al Hajjar 2010 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
4 American Academy of Pediatrics 
Committee on Infectious Diseases 2004 
The article describes an advice that is not based on a systematic review 
5 Anderson 2001 The content of this article does not provide data that meet the objectives 
6 Anderson 2002 This article does not describe results for the population of interest 
7 Anderson 2003 This article does not describe results for the population of interest 
8 Anderson 2005 The content of this article does not provide data that meet the objectives 
9 Ansaldi 2004 This article does not describe results for the population of interest 
10 Ansaldi 2005 This article does not meet the CoCanCPG requirements for conducting a cohort 
study 
11 Arias 2003 The content of this article does not provide data that meet the objectives 
12 Arostegi Kareaga 2005 This article does not describe results for the population of interest 
13 Aull 2007 This article does not describe results for the population of interest 
14 Badia Llach 2006 The content of this article does not provide data that meet the objectives 
15 Baguelin 2010 This concerns a modelling study 
16 Barr 2005 The content of this article does not provide data that meet the objectives 
17 Baydur 2004 The content of this article does not provide data that meet the objectives 
18 Beard 2006 The content of this article does not provide data that meet the objectives 
19 Belgian Working Group on Influenza 
A(H1N1) 2009 
The content of this article does not provide data that meet the objectives  
20 Bender 2009 The content of this article does not provide data that meet the objectives 
21 Beyer 2002 The content of this article does not provide data that meet the objectives 
22 Bigl 2002 This article does not describe results for the population of interest 
23 Blake 2009 The article describes an advice that is not based on a systematic review 
24 Bobo 2009 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
25 Bourgeois 2009 The methods section is not clear 
26 Bourgeois 2006 The content of this article does not provide data that meet the objectives 
27 Boyd 2006 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
28 Bramley 2009 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
29 Brouard 2007 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
30 Bryant 2010 The content of this article does not provide data that meet the objectives 
31 Burgner 2005 The content of this article does not provide data that meet the objectives 
32 Bürkle 2010 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
33 Calatayud 2010 The study population described in this article is too small to include in the 
review, data only from only one school in London 
34 Calitri 2010 The study population described in this article is too small to include in the 
review 
35 Callaghan 2010 The content of this article does not provide data that meet the objectives 
36 Calvo Rey 2005 This article does not describe results for the population of interest 
37 Calvo 2006 The study population described in this article is too small to include in the 
review 
38 Carmona 2010 The article describes a Phase II trial 
39 Carrat 2006 This is a modelling study 
40 Castilla 2005 This article does not describe results for the population of interest 
41 CDC 2009 Another selected article describes the same study population but presents more 
complete or more recent data  
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42 CDC 2003 This article does not describe results for the population of interest 
43 CDC 2004 This article does not describe results for the population of interest 
44 CDC 2004 This article does not describe results for the population of interest 
45 CDC 2004 This article does not describe results for the population of interest 
46 CDC 2004 This article does not describe results for the population of interest 
47 CDC 2006 This article does not describe results for the population of interest 
48 CDC 2008 The results in this article are described in another article 
49 CDC 2009 The results in this article are described in another article 
50 CDC 2009 The content of this article does not provide data that meet the objectives 
51 CDC 2009 This article does not describe results for the population of interest 
52 CDC 2010 This article does not describe results for the population of interest 
53 Chandran 2005 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
54 Chen 2009 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
55 Chung 2007 The content of this article does not provide data that meet the objectives 
56 Committe on Infectious Diseases. 
American Academy of Pediatrics 2002 
The article describes an advice that is not based on a systematic review 
57 Coleman 2006 The content of this article does not provide data that meet the objectives 
58 Cox 2004 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
59 Cox 2006 J Womens Health This article does not describe results for the population of interest 
60 Cox 2006 Obstet Gynecol The content of this article does not provide data that meet the objectives 
61 Crighton 2004 The content of this article does not provide data that meet the objectives 
62 Crighton 2007 The content of this article does not provide data that meet the objectives 
63 Crum-Cianflone 2009 The content of this article does not provide data that meet the objectives  
64 D'Agaro 2008 This article does not describe results for the population of interest 
65 Daley 2000 This article does not describe results for the population of interest 
66 David 2005 This article does not describe results for the population of interest 
67 De Donno 2007 This article does not describe results for the population of interest 
68 Delore 2006 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
69 Dickinson 2002 The content of this article does not provide data that meet the objectives 
70 Dodds 2007 The content of this article does not provide data that meet the objectives 
71 Doyle 2006 This concerns a modelling study 
72 Durando 2010 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
73 Ehlken 2005 The data in this study are derived from another included study 
74 Ellis 2003 The content of this article does not provide data that meet the objectives 
75 Eriksson 2000 The content of this article does not provide data that meet the objectives 
76 Esposito 2008 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
77 Esposito 2009 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
78 Fairbrother 2010 Another selected article describes the same study population but presents more 
complete or more recent data  
79 Falagas 2010 The articles included in this review are judged/described seperately 
80 Falchi 2008 The content of this article does not provide data that meet the objectives 
81 Fleming 2005 The study period described in the article does not include the period of the 
review 
82 Fleming 2005 The content of this article does not provide data that meet the objectives 
83 Fleming 2007 This article does not describe results for the population of interest 
84 Fleming 2008 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
85 Forster 2003 More complete data is available for this country 
86 Frank 2010 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
87 Fujii 2002 This article does not describe results for the population of interest 
88 Gabutti 2004 This article does not describe results for the population of interest 
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89 García-García 2006 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
90 Gautier 2008 The content of this article does not provide data that meet the objectives 
91 Giezeman 2009 The content of this article does not provide data that meet the objectives 
92 Girard 2010 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
93 Glezen 2002 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
94 Glezen 2004 The study period described in the article does not include the period of the 
review 
95 Goddard 2004 The content of this article does not provide data that meet the objectives 
96 Goldrick 2004 The content of this article does not provide data that meet the objectives 
97 Griffin 2004 More complete data is available for this country 
98 Grose 2004 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
99 Groupe de Travail 2005 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
100 Groupe de Travail 2005 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
101 Grupo de Trabajo 2010 This article described a systematic review, but the evidence is solely based on 
expert opinions  
102 Guarner 2006 This article does not describe results for the population of interest 
103 Guillain-Barre syndrome study group 
2000 
This article does not describe results for the population of interest 
104 Hackett 2009 The study population described in this article is too small to include in the 
review 
105 Hannoun 2004 The content of this article does not provide data that meet the objectives 
106 Hanslik 2010 No clear description of methodology-study partly based on estimations 
107 Hara 2007 The content of this article does not provide data that meet the objectives 
108 Harper 2004 The study period described in the article does not include the period of the 
review 
109 Health Protection Agency and Health 
Protection Scotland New Influenza 
A(H1N1) Investigation Teams 2009 
More complete data is available for this country  
110 Healy 2006 The content of this article does not provide data that meet the objectives 
111 Hehme 2002 This article does not describe results for the population of interest 
112 Heikkinen 2006 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
113 Heikkinen 2006 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
114 Heininger 2003 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
115 Henrickson 2004 The content of this article does not provide data that meet the objectives 
116 Heron 2007 This article does not describe results for the population of interest 
117 Heron 2007 The content of this article does not provide data that meet the objectives 
118 Herzog 2009 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
119 Hjalmarsson 2009 This article does not describe results for the population of interest 
120 Hoskins 1973 The study period described in the article does not include he period of the 
review  
121 Hoyert 2005 The content of this article does not provide data that meet the objectives 
122 Hoyert 2006 The content of this article does not provide data that meet the objectives 
123 Hsieh 2006 The content of this article does not provide data that meet the objectives 
124 Hunter 2005 More complete data is available for this country 
125 Iskander 2007 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
126 Iskander 2009 The content of this article does not provide data that meet the objectives 
127 Iwane 2004 The study population described in this article is too small to include in the 
review 
128 Jaber 2010 The articles included in this review are judged/described seperately 
129 Jamieson 2009 More complete data is available for this country 
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130 Jansen 2007 This article does not describe results for the population of interest 
131 Jansen 2008 The content of this article does not provide data that meet the objectives 
132 Jefferson 2005 The results in this article are described in another article 
133 Jefferson 2008 The articles about Europe included in this review are judged/described 
seperately 
134 Jensen 2004 The content of this article does not provide data that meet the objectives 
135 Jensen-Fangel 2004 The content of this article does not provide data that meet the objectives 
136 Joiner 2002 This article does not describe results for the population of interest 
137 Jouvet 2010 This article does not describe results for the population of interest 
138 Kappagoda 2000 This article does not describe results for the population of interest 
139 Kelly 2009 This article does not describe results for the population of interest 
140 Kikuchi 2007 This article does not describe results for the population of interest 
141 Kotikoski 2002 The content of this article does not provide data that meet the objectives 
142 Kroll 2006 The content of this article does not provide data that meet the objectives 
143 Kumar 2009 This article does not describe results for the population of interest 
144 Kunzi 2009 This article does not meet the CoCanCPG requirements on describing a cohort 
study 
145 Kwong 2006 The content of this article does not provide data that meet the objectives 
146 Laibl 2005 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
147 Lambert 2005 The content of this article does not provide data that meet the objectives 
148 Lambert 2007 This article does not describe results for the population of interest 
149 Lapinsky 2010 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
150 Larcombe 2010 The study population described in this article is too small to include in the 
review 
151 Laundy 2003 This article does not describe results for the population of interest 
152 Lee 2010 This article does not describe results for the population of interest 
153 Lee 2010 This article does not describe results for the population of interest 
154 Lemay 2008 The content of this article does not provide data that meet the objectives 
155 Lenglet 2007 The content of this article does not provide data that meet the objectives 
156 Leroux-Roels 2009 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
157 Li 2007 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
158 Li 2007 This article does not describe results for the population of interest 
159 Li 2009 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
160 Lister 2009 The content of this article does not provide data that meet the objectives 
161 Loughlin 2003 The study period described in the article does not include the period of the 
review 
162 Louie 2006 This article does not describe results for the population of interest 
163 Louie 2009 The results in this article are described in another selected article that will be 
included in the evidence table 
164 Lum 2009 The content of this article does not provide data that meet the objectives 
165 Macey 2003 This article does not describe results for the population of interest 
166 Mahlmeister 2009 The content of this article does not provide data that meet the objectives 
167 Mak 2008 The content of this article does not provide data that meet the objectives 
168 Manzoli 2007 The articles about Europe included in this review are judged/described 
seperately 
169 Marchetti 2007 This study concerns a modelling study 
170 Marès 2010 The article describes an advice that is not based on a systematic review 
171 Mares Bermudez 2010 This article does not meet the CoCanCPG requirements for conducting a 
systematic review 
172 Martin 2009 Another selected article describes the same study population but presents more 
complete or more recent data  
173 Mashiba 2004 The study population described in this article is too small to include in the 
review, data from only one hospital 
174 Matsuzaki 2006 The study period described in the article does not include the period of the 
review 
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175 Matsuzaki 2007 The content of this article does not provide data that meet the objectives 
176 Mazick 2010 The content of this article does not provide data that meet the objectives 
177 Meier 2000 The study period described in the article does not include the period of the 
review 
178 Meijer 2006 This article does not describe results for the population of interest 
179 Meijer 2007 This article does not describe results for the population of interest 
180 Meissner 2001 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
181 Meissner 2007 The article describes an advice that is not based on a systematic review 
182 Meury 2004 The content of this article does not provide data that meet the objectives 
183 Minino 2001 The content of this article does not provide data that meet the objectives 
184 Minino 2006 The content of the article does not provide data for the objectives 
185 Minino 2007 The content of this article does not provide data that meet the objectives 
186 Mizuta 2004 The content of this article does not provide data that meet the objectives 
187 Molinari 2007 The content of this article does not provide data that meet the objectives 
188 Monto 2002 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
189 Moore 2006 This article does not describe results for the population of interest 
190 Morishima 2002 The content of this article does not provide data that meet the objectives 
191 Munoz 2002 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
192 Murakami 2007 This article does not describe results for the population of interest 
193 National Advisory Committee on 
Immunisation (NACI) 2005 
The article describes an advice that is not based on a systematic review 
194 National Advisory Committee on 
Immunisation (NACI) 2006 
The article describes an advice that is not based on a systematic review 
195 Navarro-Mari 2003 This article does not describe results for the population of interest 
196 Negri 2005 The articles about Europe included in this review are judged/described 
seperately 
197 Newall 2008 The content of this article does not provide data that meet the objectives 
198 Nicholson 2003 The content of this article does not provide data that meet the objectives 
199 Nicoll 2008 The content of this article does not provide data that meet the objectives 
200 Nicoll 2010 The article describes an advice that is not based on a systematic review 
201 No authors listed 2005 This article does not describe results for the population of interest 
202 No authors listed Arch Dis Child 2002 The content of this article does not provide data that meet the objectives 
203 No authors listed Can Commun Dis Rep 
2006 
Another selected article describes the same study population but presents more 
complete or more recent data  
204 No authors listed N.S.W.Public Health 
Bull 2002 
This article does not describe results for the population of interest 
205 No authors listed N.S.W.Public Health 
Bull 2003 
This article does not describe results for the population of interest 
206 No authors listed Wkly Epidemiol Rec 
2002 
The content of this article does not provide data that meet the objectives 
207 No authors listed Wkly Epidemiol Rec, 
Epidemiological summary... 2009 
This article does not describe results for the population of interest 
208 No authors listed Wkly Epidemiol Rec, 
Human infection... 2009 
The article describes an advice that is not based on a systematic review  
209 Nougairède 2010 This article does not describe results for the population of interest 
210 Nougairède 2010 This article does not describe results for the population of interest 
211 Novel influenza A(H1N1) investigation 
team 2009 
The results in this article are described in another article 
212 Odaira 2009 This article does not describe results for the population of interest 
213 Ohta 2007 This article does not describe results for the population of interest 
214 Okumura 2005 The content of this article does not provide data that meet the objectives 
215 Olson 2007 The content of this article does not provide data that meet the objectives 
216 O'Riordan 2010 This article does not describe results for the population of interest 
217 Ostlund 2004 The study period described in the article does not include the period of the 
review 
218 Paget 2003 This article does not describe results for the population of interest 
219 Paget 2005 The content of this article does not provide data that meet the objectives 
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220 Peltola 2002 The content of this article does not provide data that meet the objectives 
221 Peltola 2003 The study period described in the article does not include the period of the 
review 
222 Pineda Solas 2006 The article describes an advice that is not based on a systematic review  
223 Pitman 2007 This article does not describe results for the population of interest 
224 Plessa 2010 The study population described in this article is too small to include in the 
review 
225 Ploin 2003 More complete data is available for this country 
226 Podda 2003 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
227 Podewils 2005 This article does not meet the CoCanCPG requirements for conducting a cohort 
study 
228 Poland 2001 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
229 Pons-Catalano 2003 The content of this article does not provide data that meet the objectives 
230 Principi Emerg Infect Dis 2004 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
231 Principi Arch Dis Child 2004 The content of this article does not provide data that meet the objectives 
232 Principi Lancet Infect Dis 2004 This article does not meet the CoCanCPG requirements for conducting a 
systematic review 
233 Principi Pedatr Infect Dis J 2003 The results in this article are described in another article 
234 Prisco 2002 This article does not describe results for the population of interest 
235 Quach 2003 This article does not describe results for the population of interest 
236 Ramet 2007 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
237 Rebmann 2008 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
238 Regan Euro Surveill 2002 This article does not describe results for the population of interest 
239 Reina 2005 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
240 Rello 2009 The study population described in this article is too small to include in the 
review 
241 Rennels 2002 This article does not meet the CoCanCPG requirements for conducting a 
systematic review 
242 Reyes 2007 Another selected article describes the same study population but presents more 
complete or more recent data  
243 Reyes 2008 Another selected article describes the same results 
244 Rezza 2006 This article does not describe results for the population of interest 
245 Richards 2005 The article describes an advice that is not based on a systematic review  
246 Ritz 2008 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
247 Rizzo 2009 The content of this article does not provide data that meet the objectives 
248 Roberts 2006 More complete data is available for this country 
249 Rodríguez 2010 The content of this article does not provide data that meet the objectives 
250 Rothberg 2008 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
251 Rubín 2010 This article describes a case serie or case report 
252 Ryan 2006 The content of this article does not provide data that meet the objectives 
253 Salo 2006 This is a modelling study 
254 Sasaki 2005 This article does not describe results for the population of interest 
255 Satpathy 2009 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
256 Savidan 2008 The articles about Europe included in this review are judged/described 
seperately 
257 Schanzer 2006 The content of this article does not provide data that meet the objectives 
258 Schmitt-Grohe 2001 This article does not meet the CoCanCPG requirements for conducting a clinical 
trial 
259 Sebastian 2008 The content of this article does not provide data that meet the objectives 
260 Sebastian 2009 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
261 Sessa 2001 This article does not describe results for the population of interest 
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262 Silvennoinen 2009 This article does not meet the CoCanCPG requirements for conducting a cohort 
study 
263 Sivaprakasam 2008 The content of this article does not provide data that meet the objectives 
264 Smith Cochrane Database Syst Rev 
2006 
The results in this article are described in another article 
265 Smith MMWR Recomm Rep 2006 2006 The article describes an advice that is not based on a systematic review 
266 Stowe 2009 The content of this article does not provide data that meet the objectives 
267 Stuart 2009 The article describes an advice that is not based on a systematic review  
268 Studahl 2003 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
269 Sugaya 2002 This article does not describe results for the population of interest 
270 Surveillance Group for New Influenza 
A(H1N1) Virus Investigation and 
Control in Spain 2009 
This article does not describe results for the population of interest 
271 Sypsa 2009 This concerns a modelling study 
272 Szucs 2004 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
273 Takanashi 2009 The study population described in this article is too small to include in the 
review 
274 Takano 2009 The content of this article does not provide data that meet the objectives 
275 Teo 2005 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
276 Terebuh 2003 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
277 Thompson 2003 The content of this article does not provide data that meet the objectives 
278 Thompson 2004 The study period described in the article does not include the period of the 
review 
279 Thompson 2006 The content of this article does not provide data that meet the objectives 
280 Toovey 2008 The study period described in the article does not include the period of the 
review 
281 Toschke 2008 The content of this article does not provide data that meet the objectives 
282 Trollfors 2006 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
283 Turbelin 2009 The content of this article does not provide data that meet the objectives 
284 Turner 2003 The content of this article does not provide data that meet the objectives 
285 Uphoff 2004 This article does not describe results for the population of interest 
286 Vabret 2010 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
287 Vaillant 2009 This article does not describe results for the population of interest 
288 Vajo 2008 The study population described in this article is too small to include in the 
review 
289 van der Wouden 2005 The results in this article are described in another article 
290 van der Zee 2000 The study period described in the article does not include the period of the 
review 
291 van Esso Arbolave 2006 The study population described in this article is too small to include in the 
review 
292 van Zeijl 2004 The content of this article does not provide data that meet the objectives 
293 Vesikari 2008 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
294 Vynnycky 2008 This concerns a modelling study 
295 Wahlberg 2003 The content of this article does not provide data that meet the objectives 
296 Wang 2010 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
297 Wareing 2001 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
298 Wareing 2002 The content of this article does not provide data that meet the objectives 
299 Watanabe 2003 The study population described in this article is too small to include in the 
review 
300 Weil-Olivier 2004 The article does not meet the CoCanCPG requirements for conducting a 
systematic review 
301 Weir 2003 The content of this article does not provide data that meet the objectives 
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Annex 3. Summary tables  
Table 2. Laboratory-confirmed pandemic influenza A(H1N1) incidence in children 0−4 years old 
Author, 
year 
Country Season Study population No. of cases* Outcome measure  Age 
group 
(years)  
Results 
 
Europe        
Donaldson, 
200915 
England 2009  
(July-Nov) 
population of 
England, all ages 
NA estimated cumulative 
incidence per 100 000 
population  
< 1 
1-4  
1 000  
1,100 
Gilsdorf  
200973 
Germany 2009 
(April-Aug) 
population of 
Germany, all ages 
first 9,950 
cases  
cumulative incidence 
per 100 000 
population 
Up to 2 5.5 
Hahné,  
200974 
The 
Netherlands 
2009 
(April-June) 
population of the 
Netherlands, all ages 
51 indigenous 
cases 
proportion of cases 0-4 4% 
Poggensee 
201075 
Germany 2009  
(April-Nov) 
population of 
Germany, all ages 
53,968 proportion of cases  0-4 4% 
Levy-Bruhl, 
200976 
France 2009 
(April-July) 
population of 
France, all ages 
90 indigenous 
cases 
proportion of cases 0-9  30% 
McLean 
201014 
UK 2009  
(April-June) 
population of the 
UK, all ages (FF100 
project) 
392 proportion of cases  < 1  
1-5  
 
0.8% 
9.2% 
Other Western countries 
Appuhamy 
200977 
Australia 2009  
(April-June) 
population of 
Queensland, all ages 
593 cumulative incidence 
per 100 000 
population 
0-4  21.6 
CDC, Ritger, 
20096 
US 2009 
(April-July) 
Chicago residents, all 
ages 
1,557 cumulative incidence 
per 100 000 
population 
0-4 113 
Paine 201010  New Zealand 2009  
(April-Nov) 
population of New 
Zealand, all ages 
3,186 cumulative incidence 
per 100 000 
population 
< 1  
1-4 
223 
97 
Baker, 200978 New Zealand 2009 
(April- Aug) 
population of New 
Zealand, all ages 
3,179 cumulative incidence 
per 100 000 
population 
< 1 218.5 
Reed 200979 US 2009 (April-
July) 
population of the 
US, all ages 
NA estimated cumulative 
incidence (90% CI) 
per 100 000 
population 
0-4  1,870 
(1,122-
3,505) 
Kelly, 200980 Australia 2009 
(April-July) 
population of 
Victoria, all ages 
221 proportion of cases 0-4 
 
3% 
 
New South 
Wales public 
health 
network 
20099 
Australia 2009  
(May-Aug) 
population of New 
South Wales, all 
ages 
5,106 relative risk 
(comparison with the 
general population) 
0-4  1 
* All cases were laboratory-confirmed cases. 
  
Table 3. Laboratory-confirmed pandemic influenza A(H1N1) incidence in children ≥ 5 years old 
Author, year Country Season Study population No. of cases* Outcome measure  Age group  Results 
 
Europe        
Gilsdorf 200973 Germany 2009 
(April-Aug) 
population of 
Germany, all ages 
first 9,950 
cases  
cumulative incidence 
per 100 000 
population 
15-19 90 
Donaldson 
200915 
England 2009  
(July-Nov) 
population of 
England, all ages 
NA estimated cumulative 
incidence per 100 000 
population  
5-14 
 
3,100 
 
Poggensee 
201075 
Germany 2009  
(April-Nov) 
population of 
Germany, all ages 
53,968 proportion of cases  5-14  32% 
McLean 201014 UK 2009  
(April-June) 
population of the UK, 
all ages (FF100 
project) 
392 proportion of cases  6-15 
 
42.3% 
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Author, year Country Season Study population No. of cases* Outcome measure  Age group  Results 
 
Levy-Bruhl, 
200976 
France 2009 
(April-July) 
population of France, 
all ages 
90 indigenous 
cases 
proportion of cases 10-19  31% 
Hahné, 200974 The 
Netherlands 
2009 
(April-June) 
population of the 
Netherlands, all ages 
51 indigenous 
cases 
proportion of cases 5-9 
10-14 
15-19 
22% 
16% 
12% 
Other Western countries 
CDC, Ritger6 US 2009 
(April-July) 
Chicago residents, all 
ages 
1,557 incidence rate per 
100 000 population 
5-14 147 
Appuhamy 
200977  
Australia 2009  
(April-June) 
population of 
Queensland, all ages 
593 cumulative incidence 
per 100 000 
population 
5-9 
10-14 
15-19 
16.8 
28.7 
27.6 
Paine 201010  New Zealand 2009 
(April-Nov) 
population of New 
Zealand, all ages 
3,186 cumulative incidence 
per 100 000 
population 
5-9  
10-14 
15-19 
84 
92 
127 
Kelly, 200980 Australia 2009 
(April-July) 
population of 
Victoria, all ages 
221 proportion of cases  15-19 37% 
New South 
Wales Public 
Health network 
20099 
Australia 2009  
(May-Aug) 
population of New 
South Wales, all 
ages 
5,106 relative risk 
(comparison with the 
general population) 
5-9 
10-14 
15-19  
1.6 
1.7 
1.4 
* All cases were laboratory-confirmed cases.  
  
Table 4. Laboratory-confirmed pandemic influenza A(H1N1) hospitalisations in children 0–4 years old 
Author, year Country Season No. of 
hospitalisations in 
total study group* 
Outcome measure  Age group 
(years) 
Results 
 
Europe       
Cullen, 20094 Ireland 2009 
(April-Oct) 
205 hospitalisations, 
all ages 
hospitalisation rate 
per 100 000 
population  
0-4  
  
9.7 
 
Van ‘t Klooster 
20103  
 
the 
Netherlands 
2009 
(June-Dec) 
1,962 
hospitalisations 
(non-ICU), all ages 
hospitalisation (non-
ICU) rate per 100 000 
population 
0-4  62.7 
Fuhrman, 20101 France 2009 (July-
Nov) 
514 hospitalised 
patients, 244 severe 
cases, all ages 
rate of admission to 
ICU per 100 000 
population 
< 1 2.03 
Koliou, 200913 Cyprus 2009 
(June-Aug) 
5 hospitalised 
patients < 16 yrs 
proportion 
hospitalisation of 
influenza cases 
0-16  11% (5/45) 
Nguyen-Van-
Tam, 20102 
UK 2009  
(April - Sept) 
631 hospitalisations, 
all ages 
proportion of 
hospitalised influenza 
cases 
< 1  
1-4 
7% 
9% 
Fuhrman, 20101 France 2009 
 (July-Nov) 
514 hospitalised 
patients, 244 severe 
cases, all ages 
proportion of 
hospitalised severe 
influenza cases 
 
< 1  
1-14  
7% 
13% 
Other Western countries     
Baker, 200978 New Zealand 2009 
(April-Aug) 
972 hospitalisations, 
all ages 
hospitalisation rate 
per 100 000 
population 
< 1 149.8 
CDC (Ritger), 
20096 
US 2009 
(April-July) 
205 hospitalisations, 
all ages 
hospitalisation rate 
per 100 000 
population  
0-4 25 
 
CDC (Brammer), 
20107  
US 2009  
(Aug-Jan) 
 hospitalisation rate 
per 100 000 
population 
0-4 59 
New South 
Wales Public 
Health Network 
20099 
Australia 2009 
(May-Sept) 
1,214 
hospitalisations, all 
ages 
hospitalisation rate 
per 100 000 
population 
0-4 56.5 
 
Reed, 200979 US 2009  
(April-July) 
2,768 estimated 
hospitalisations, < 5 
yrs 
estimated 
hospitalisation rate 
(90% CI) per 100 000 
population 
0-4 13.0 
 (8.8-20.2) 
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Author, year Country Season No. of 
hospitalisations in 
total study group* 
Outcome measure  Age group 
(years) 
Results 
 
Presanis, 200911 US 2009  
(April-July) 
259 hospitalisations,  
< 5 yrs 
estimated proportion 
of cases that result in 
hospitalisation (95% 
CI) 
0-4 2.45  
(1.10%-5.56%) 
Bettinger, 20105  Canada 2009  
(May-Aug) 
235 hospitalised 
patients <16 yrs 
proportion of 
hospitalised patients 
< 3 months 
3-5 months 
6-23 months 
2-5 yrs 
6.4% 
3.8% 
20.9% 
28.1% 
Jain, 20098 US 2009 
(May-June) 
272 hospitalisations, 
all ages 
proportion of 
hospitalised patients 
0-2 
2-4 
 
8% 
7% 
 
Tuite, 201012 Canada 2009  
(April-June) 
140 hospitalisation, 
all ages 
risk (odds ratio (95% 
CI) of hospital 
admission 
< 1  
 
1-11 
 
5.86 
 (2.65-12.94) 
1.46  
(0.95-2.26) 
* All cases were laboratory-confirmed cases. 
 
Table 5. Laboratory-confirmed pandemic influenza A(H1N1) hospitalisations in children ≥5 years old 
Author, year Country Season No. of 
hospitalisations in 
total study group*  
Outcome measure  Age group 
(years)  
Results 
Europe       
Cullen, 20094 Ireland 2009 
(April-Oct) 
205 
hospitalisations, all 
ages 
hospitalisation rate per 
100 000 population  
5-9  
10-14 
15-19  
6.1 
4.7 
10.2 
Van ‘t Klooster 
20103  
 
the 
Netherlands 
2009  
(June-Dec) 
1,962 
hospitalisations 
(non-ICU), all ages 
hospitalisation (non-ICU) 
rate per 100 000 
population 
5-14  19.3 
Nguyen-Van-
Tam, 20102 
UK 2009 
(April - Sept) 
631 
hospitalisations, all 
ages 
proportion of hospitalised 
patients 
5-15  20% 
Other Western countries     
CDC (Ritger), 
20096 
US 2009 
(April-July) 
205 
hospitalisations, 
all ages 
hospitalisation rate per 
100 000 population  
5-14 11 
CDC 
(Brammer), 
20107  
US 2009 
(Aug-Jan) 
 hospitalisation rate per 
100 000 population 
5–17  25 
Paine, 201010  New Zealand 2009  
(April-Nov) 
1,008 hospitalised 
patients, any age 
hospitalisation rate per 
100 000 population 
5-9  
10-14  
15-19  
17 
19 
23 
New South 
Wales, 20099 
Australia 2009 
(May-Sept) 
1,214 
hospitalisations, all 
ages 
hospitalisation rate per 
100 000 population 
5-9 
10-14 
15-19 
15.8 
9.6 
13.6 
Presanis, 200911 US 2009  
(April-July) 
232 
hospitalisations, 5-
17 yrs 
estimated proportion of 
cases that result in 
hospitalisation (95% CI) 
5-17 0.61% (0.27%-
1.34%) 
Bettinger, 20105  Canada 2009  
(May-Aug) 
235 hospitalised 
patients <16 yrs 
proportion of hospitalised 
patients 
6-12  
13-15 
26.8% 
14% 
Jain, 20098 US 2009 
(May-June) 
272 
hospitalisations, all 
ages 
proportion of hospitalised 
patients 
5-9 
10-17 
11% 
18% 
Tuite, 201012 Canada 2009  
(April-June) 
140 hospitalisation, 
all ages 
risk (odds ratio (95% CI) 
of hospital admission 
12-18 0.45  
(0.26-0.81) 
* All cases were laboratory-confirmed cases.  
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Table 6. Laboratory-confirmed pandemic influenza A(H1N1) mortality in children 0-4 years old 
 
Author, year Country Season Study population Influenza 
hospitalisations 
No. of fatal 
cases 
Outcome 
measure  
Age group 
(years)  
Results 
Europe         
Van ‘t Klooster, 
20103  
The 
Netherlands 
2009  
(June-
Dec) 
population of 
the Netherlands, 
all ages 
1,962 53  mortality rate 
per 100 000 
population 
0-4 0.54 
Donaldson 200915 England 2009  
(July-Nov) 
population of 
England, all 
ages 
NR 138  estimated case 
fatality rate 
(range) per 
100 000 cases 
< 1  
1-4  
30 (2-260) 
27 (3-120) 
      proportion of 
children among 
deaths 
< 1  
 
1-4  
2 of 138 
(1%) 
7 of 138 
(5%) 
Cullen, 20094 Ireland 2009 
 (April-
Oct) 
population of 
Ireland, all ages 
205 4 proportion of 
children among 
deaths 
0-4 0% 
Fuhrman, 20101  France 2009 
 (July-
Nov) 
population of 
France, all ages 
514 37 fatal cases 
in hospitalised 
population 
proportion of 
children among 
deaths 
< 1  2 of 37 (5%) 
  proportion fatal 
cases of age-
specific 
hospitalised 
severe influenza 
cases 
< 1  2 of 16 
(12.5%) 
Koliou, 200913 Cyprus 2009 
(June-
Aug) 
children of 
Cyprus, < 16 yrs 
5 0 proportion of 
children among 
deaths 
0-4 0% 
McLean, 201014 UK 2009 
 (April-
June) 
population of 
the UK, all ages 
NR 0 proportion of 
children among 
deaths 
0-4  0% 
Pebody, 201016 England April 2009 
– March 
2010 
Population on 
England, all 
ages 
NR 336 fatal 
cases with 
information 
on age 
Proportion of 
children among 
deaths  
6 months 4 of 336 
(1%) 
Other Western countries       
CDC, 2010  
(Brammer)7 
US 2009  
(Aug-Jan) 
large sample of 
the population, 
all age 
NR 1,779 mortality rate 
per 100 000 
population 
0-4 0.31 
Kamigaki 200918 Japan 2009  
(April-
Dec) 
population of 
Japan, all ages 
10,487 85 mortality rate 
per 100 000 
population 
0-4 0.2 
New South Wales 
Public Health 
network 20099 
Australia 2009  
(May-Aug) 
population of 
New South 
Wales, Australia, 
all ages 
1,214 48  mortality rate 
per 100 000 
population 
0-4 0.0 
Presanis, 200911 US 2009  
(April-
July) 
population of 
Milwaukee and 
New York City, 
all ages 
259 132 estimated 
proportion of 
cases that result 
in death (95% 
CI) in total US 
population 
0-4 0.026% 
(0.006%-
0.092%) 
CDC 
(Shannon)200917 
US 2009  
(April-
Aug) 
population of 
US, < 18 yrs 
NR 36 proportion of 
children among 
deaths 
0-4 7 of 36 
(19%) 
Bettinger, 20105  Canada 2009  
(May-Aug) 
paediatric 
patients in 
Canada, < 16 
yrs 
253 2 proportion of 
deaths among 
reported cases in 
age group 
0-6 
months 
6-23 
months 
2-5 yrs 
0 of 24 (0%)  
 
0 of 39 (0%)  
 
0 of 66 (0%) 
Paine, 201010  New Zealand 2009  
(April-
Nov) 
population of 
New Zealand, all 
ages 
263 19  proportion of 
children among 
deaths 
<1  
1-4  
0 of 19 (0%) 
1 of 19 
(5.3%) 
      proportion of 
deaths among 
reported cases in 
age group 
<1  
 
1-4  
0 of 143 
(0%) 
1 of 230 
(<1%) 
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Table 7. Laboratory-confirmed pandemic influenza A(H1N1) related mortality in children ≥ 5 years 
old 
Author, year Country Season Study 
population 
Influenza 
hospitalisations 
No. of fatal 
cases 
Outcome 
measure  
Age 
group 
(years) 
Results 
Europe         
Van ‘t 
Klooster, 
20103  
Netherlands 2009 
 (June-
Dec) 
population of 
Netherlands, all 
ages 
1,962 53  mortality rate 
per 100 000 
population 
5-14  0.45 
 
Donaldson 
200915 
England 2009  
(July-Nov) 
population of 
England, any 
age 
NR 138  estimated case 
fatality rate 
(range) per 
100 000 cases  
5-14  11 (3-36) 
 
      proportion of 
children among 
deaths 
5-14 
 
20 of 138 
(14%) 
Cullen, 20094 Ireland 2009  
(April-Oct) 
population of 
Ireland, all ages 
205 4 proportion of 
children among 
deaths 
5-15  0% 
Fuhrman, 
20101  
France 2009  
(July-Nov) 
population of 
France, any age 
514 37 fatal cases 
in hospitalised 
population 
proportion of 
children among 
deaths 
1-14  3 of 37 
(8%) 
 244 
hospitalised 
severe 
influenza 
cases 
proportion of 
deaths among 
age-specific 
hospitalised 
severe influenza 
cases 
1-14 3 of 32 
(9.4%) 
Koliou, 
200913 
Cyprus 2009 
(June-
Aug) 
children of 
Cyprus, < 16 yrs 
5 0 proportion of 
children among 
deaths 
5-16  0% 
McLean, 
201014 
UK 2009 
 (April-
June) 
population of 
the UK, all ages 
NR 0 proportion of 
children among 
deaths 
5-15  0% 
Nguyen-Van-
Tam, 20102 
UK 2009  
(April-
Sept) 
hospitalised 
patients in the 
UK, all ages 
631 29  case fatality 
rate in 
hospitalised 
patients 
0-15  3.5% 
Other Western countries       
CDC, 2010  
(Brammer)7 
US 2009  
(Aug-Dec) 
large sample of 
the population, 
all age 
NR 1,779 mortality rate 
per 100 000 
population 
5-18 0.26 
Kamigaki 
200918 
Japan 2009  
(April-Dec) 
population of 
Japan, all ages 
10,487 85 mortality rate 
per 100 000 
population 
5-9  
10-14  
15-19  
0.1 
0.07 
0.02 
New South 
Wales Public 
Health 
network 
20099 
Australia 2009  
(May-Aug) 
population of 
New South 
Wales, Australia, 
all ages 
1,214 48  mortality rate 
per 100 000 
population 
5-9  
10-14  
15-19  
0.2 
0.0 
0.0 
Presanis, 
200911 
US 2009  
(April-
July) 
population of 
Milwaukee and 
New York City, 
all ages 
232 132 estimated 
proportion of 
cases that result 
in death (95% 
CI) in total US 
population 
5-17 0.010% 
(0.003%-
0.031%) 
CDC 
(Shannon), 
200917 
US 2009  
(April-
Aug) 
population of 
US, < 18 yrs 
NR 36 proportion of 
children among 
deaths 
5-17  29 of 36 
(81%) 
Fielding, 
200959 
Australia 2009 
(May-
Sept) 
population of 
Victoria, 
Australia, all 
ages 
NR 24 proportion of 
children among 
deaths 
0-18  3 of 24 
(12.5%) 
Paine, 201010  New Zealand 2009  
(April-
Nov) 
population of 
New Zealand, 
any age 
263 19  proportion of 
children among 
deaths 
5-9 
 
10-14 
 
15-19  
1 of 19 
(5.3%) 
0 of 19 
(0%) 
0 of 19 
(0%) 
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Author, year Country Season Study 
population 
Influenza 
hospitalisations 
No. of fatal 
cases 
Outcome 
measure  
Age 
group 
(years) 
Results 
      proportion of 
fatal cases of 
age-specific 
notified 
influenza cases 
5-9  
 
10-14  
 
15-19  
1 of 241 
(<1%) 
0 of 279 
(0%) 
0 of 410 
(0%) 
Bettinger, 
20105  
Canada 2009  
(May-Aug) 
paediatric 
patients in 
Canada, < 16 
yrs 
235 2 proportion of 
deaths among 
reported cases 
in age group 
6-12  
 
13-16 
2 of 63 
(3%) 
0 of 33 
(0%) 
 
Table 8. Complications of laboratory-confirmed pandemic influenza A(H1N1) in children 
Author, year Country Season Study 
population  
No. of included 
cases 
Age group 
(years)  
Outcome measure Results 
Europe        
Nguyen-Van-
Tam, 20102 
UK 2009 (April-
Sept) 
Hospitalised 
patients in the 
UK, all ages 
226 hospitalised 
children 
< 18 proportion of cases with 
pneumonia 
37 of 106* 
(35%) 
Other Western countries      
Bettinger, 
20105 
Canada 2009 (May-
Aug) 
Children  
< 16 yrs in 
Canada 
324 hospitalised 
cases 
< 16 proportion of cases with: 
• Lower respiratory 
tract 
manifestations** 
• Febrile/afebrile 
seizures 
• Encephalitis 
• Aseptic meningitis 
  
67%  
 
 
4%  
 
1% 
<1% 
 
* Chest radiographic results were recorded in 106 children 
** Lower respiratory tract manifestations are either respiratory distress, wheezing or radiologically confirmed pneumonia.  
  
Table 9. Seasonal influenza-like-illness incidence in children 0−4 years old 
Author, year Country Season Study population Sample size Outcome measure Age group 
(years) 
Results 
Europe        
Castilla 
200681 
Spain 2004-2005 population of 
Navarra 
22,339 
inhabitants 
cumulative incidence of 
ILI consultations per 
100 000 inhabitants 
0-4 3,950 
Dijkstra 
200982 
The 
Netherlands 
1986-2007 population of 
Netherlands, all 
ages 
NA annual incidence range of 
ILI consultations per 
season per 100 000 
population 
< 5 1,550 (2002-
2003) – 10,110 
(1988-1989) 
Paget 201083 England Italy 
The 
Netherlands 
Spain 
2002-2008 population of 
England, Italy, 
Netherlands, and 
Spain, all ages 
NA average incidence of ILI 
consultations per 100 000 
population 
0-4   
 
England: 354 
Italy: 9229 
Netherlands: 
925 
Spain: 2,156 
Heikkinen 
200384 
Finland 2000-2001 children < 13 
years old in area 
of Turku 
University 
Hospital 
1,338 cumulative attack rate 0-13 18.8% 
Payne 200585 Sweden Week 7 (14-
20 
February), 
2005 
random sample 
of the Swedish 
population, all 
ages 
2,119 One-week prevalence of 
self-reported influenza 
0-4 
 
15.6%  
(95% CI: 8.3 
to 22.8) 
Other Western countries      
Fluwatch 
Project 
(Macey) 
200186 
Canada 2000-2001 population of 
Canada, all ages 
NA ILI peak incidence per 
100 000 population 
≤ 5 
 
2,500 
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Author, year Country Season Study population Sample size Outcome measure Age group 
(years) 
Results 
Squires 
200087 
Canada 1999-2000 population of 
Canada, all ages 
NA • cumulative incidence 
of ILI consultations 
per 100 000 
• proportion of cases 
1-4  
 
 
1-4 
7,800  
 
 
16.2% 
Public Health 
Agency of 
Canada 
200628 
Canada 2004-2005 population of 
Canada, all ages 
NA • ILI consultations peak 
incidence per 100 000 
• proportion of cases 
among total group 
0-4  
 
14,900  
 
12.4% of total 
cases 
Kawado 
200788 
Japan 2002-2005 Population of 
Japan, all ages 
NA estimated annual 
incidence per 100 000 
population, range 
0-14 
females  
 
0-14 males 
22,340 – 
46,170  
 
23,870 – 
49,040 
  
Table 10. Seasonal influenza-like-illness incidence in children ≥ 5 years old 
Author, year Country Season Study population Sample size Outcome measure Age group 
(years) 
Results 
Europe        
Castilla 
200681 
Spain 2004-2005 population of 
Navarra 
22,339 
inhabitants 
cumulative incidence per 
100 000 inhabitants 
5-14 5,040 
Paget 201083 England Italy 
Netherlands 
Spain 
2002-2008 population of 
England, Italy, 
Netherlands, and 
Spain, all ages 
NA average incidence of ILI 
consultations per 
100 000 population 
5-14 England: 315 
Italy:8,915 
Netherlands: 632 
Spain: 2,955 
Payne 200585 Sweden Week 7 (14-
20 
February), 
2005 
random sample 
of the Swedish 
population, all 
ages 
2,119 prevalence of self-
reported influenza 
5-14 13.0% (95% CI, 
8.5 to 17.5) 
Other Western countries      
Fluwatch 
Project 
(Macey) 
200186 
Canada 2000-2001 population of 
Canada, all ages 
NA ILI peak incidence per 
100 000 population 
5-19 2,700 
Public Health 
Agency of 
Canada 
200628 
Canada 2004-2005 population of 
Canada, all ages 
NA ILI consultations peak 
incidence per 100 000 
5-19 10,300 
 
Squires 
200087 
Canada 1999-2000 population of 
Canada, all ages 
NA ILI cumulative incidence 
per 100 000  
 
5-9 
10-14 
 
6,100 
NR 
 
• proportion of cases  5-9 
10-14 
3.4% 
1.9% 
 
Table 11. Seasonal influenza-like-illness or laboratory-confirmed incidence in children 0–18 years old 
Country Season Study population Outcome measure  Age group 
(years)  
Results 
 
Europe      
Englanda 2002-2005 population of England, all 
ages 
peak ILI consultation 
rates per 100 000 
population 
0-4  
5-14 
2002-2003: 54 
2003-2004: 157 
2004-2005: 62 
2002-2003: 59 
2005-2006: 97.6 
Franceb 2005-2008 population of France, all 
ages 
proportion of cases  0-14 2005: 28.5% 
2006: 44.1% 
season 2006-2007: 33.7% 
season 2007-2008: 32.7% 
Swedend 2006-2008 population of Sweden, all 
ages 
observed and expected 
number of casesxvi 
0-4  
5-14 
observed 2006-2007: 43 
expected 2006-2007: 43 
observed 2007-2008: 26 
expected 2007-2008: 32 
observed 2006-2007: 69 
expected 2006-2007: 87 
observed 2007-2008: 71 
expected 2007-2008: 65 
 
                                                                    
xvi ‘Expected’ is the number of cases that would have occurred if the cases were evenly distributed in relation to the population of 
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Country Season Study population Outcome measure  Age group 
(years)  
Results 
 
Other Western countries    
Australiae 2001-2008 population of Australia, 
all ages 
notification of laboratory-
confirmed influenza rate 
per 100 000 population, 
range 
< 1 
0-4 
5-9 
2003-2006: 75-257 
2001-2008: 32.1-166 
2001: 11.6 
2007: 68 
2008: 54 
Canadaf 2000-2008 population of Canada, all 
ages 
proportion of laboratory 
confirmed cases (range) 
0-4 
5-9 
10-14 
22% (11-33%) 
9% (3-20%) 
6% (2-19%) 
New Zealandg 2003-2009 population of New 
Zealand, all ages 
average weekly ILI 
consultation rates per 
100 000 population, 
range 
< 1 
1-4 
5-19 
44-136.5 
52.4-173.9 
40.4-93.6 
ahttp://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/SeasonalInfluenza/EpidemiologicalData/07influsInfluenzaannualr
eports/) 
b Bilans annuels 2005-2008, Le réseau Sentinelles, http://websenti.b3e.jussieu.fr/sentiweb/?rub=39 
c http://epp.eurostat.ec.europa.eu/portal/page/portal/eurostat/home/ 
d http://www.smittskyddsinstitutet.se/publikationer/arsrapporter-och-verksamhetsberattelser/smis-arsrapporter-om-
influensasasongen/) 
e http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-ozflu-2010.htm 
f http://www.phac-aspc.gc.ca/fluwatch/archive-eng.php 
g http://www.surv.esr.cri.nz/virology/influenza_annual_report.php 
 
Table 12. Laboratory-confirmed seasonal influenza hospitalisations in children 0–4 years old 
Author, year Country Season No. of hospitalisations in 
total study group 
Outcome measure  Age group 
(years)  
Results 
Europe       
Forster, 200489 Germany 1999-2001 77 hospitalisations,  
< 3 yrs 
annual hospitalisation 
rate (95% CI) per 
100 000 population 
< 3 123  
(90-163) 
Heikkinen, 200490 Finland 2000-2002 1 hospitalisation,  
< 13 yrs 
annual hospitalisation 
rate per 100 000 
population 
< 3  135 
Ploin, 200733 France 2001-2002 28 hospitalisations, 
< 3 yrs 
hospitalisation rate 
per 100 000 
population 
< 1 
1-2 
2-3 
237 
44 
23 
Montes, 200532 Spain 2001-2004 49 hospitalisations,  
< 5 yrs 
3 year hospitalisation 
rate range per 
100 000 population 
< 6 months 
6-11 months 
1-< 2 
2-< 5  
0-730 
0-170  
30-110 
10-80 
Rojo, 200634 Spain 1996-2003 146 hospitalisation,  
< 3 yrs 
8 year annual 
hospitalisation rate 
range per 100 000 
population 
< 3 11-154 
Weigl, 200219 Germany 1996-2001 122 (infl. A) 
hospitalisations, ≤16 yrs 
proportion of cases 
due to influenza A  
0-1 
> 1-2 
> 2-5 
24.5% 
23.5% 
33.3% 
Other Western countries     
CDC (Gershman), 
200522 
US 2004-2005 238 hospitalisations,  
< 18 yrs 
hospitalisation rate 
per 100 000 
population 
< 6 months 
6-23 months 
2-4  
183.0 
66.3 
28.9 
Grijalva, 2006; 
Grijalva, 2006 91;92 
 
US 2003-2005 NR hospitalisation rate 
per 100 000 
population of two 
consecutive years 
< 6 months 
6-23 months 
2-5 
 
438-910 
96-300 
20-80 
 
                                                                                                                                                                                                                                                
 
the respective age groups. 
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Author, year Country Season No. of hospitalisations in 
total study group 
Outcome measure  Age group 
(years)  
Results 
CDC (Dhara), 
2005; CDC 
Blanton, 2007; 
CDC (Epperson), 
2008; CDC 
(Peebles), 
200921;23-25 
 
US 2004-2009 NR 4 year of 
hospitalisation rate 
range per 100 000 
population 
NVSN 
0-4 
EIP 
0-4 
 
 
14.6-70  
16.2-40.3 
 
Poehling, 200631 US 2000-2004 160 hospitalisations,  
< 5 yrs 
4 years range of 
hospitalisation rate 
(95% CI) per 100 000 
population 
< 6 months 
6-23 months 
2-5 
 
230-720 
40-150 
4-60 
Dawood, 201026 US 2003-2008 4015 hospitalisation,  
< 18 yrs 
5 years range of 
hospitalisation rate 
per 100 000 
population  
< 6 months 
6-23 months 
2-4 
90-300 
30-110 
10-40 
D’Onise, 200893 Australia 1996-2006 649 hospitalisations,  
< 5 yrs 
11 years range of 
hospitalisation rate 
per 100 000 
population  
< 1 
1 
2 
3 
4 
11.6-289.0 
5.8-198.5 
0-123.2 
5.4-60.4 
0-50.9 
Hassan, 200927 US 2003 (Jan-
Dec) 
20,618 hospitalisations 
without chronic diseases, 
<18 yrs 
proportion of 
hospitalised cases 
without chronic 
diseases 
0-5 months 
6-23 months 
23% 
22% 
 
PHAC, 2006; 
Reyes 2007; 
Burton, 2008; 
Reyes, 200820;28-30 
 
Canada 2004-2008 1608 hospitalisations,  
< 16 yrs 
4 years range of 
proportion of 
hospitalised patients 
0-5 months 
6-23 months 
2-4  
14,2%-23,0% 
24,3%-31,7% 
20,2%-27.3% 
 
Table 13. Laboratory-confirmed seasonal influenza hospitalisations in children ≥5 years old 
Author, year Country Season No. of hospitalisations in 
total study group 
Outcome measure  Age group 
(years)  
Results 
Europe       
Weigl, 200219 Germany 1996-2001 122 (infl. A) 
hospitalisations, ≤ 16 yrs 
proportion of cases 
due to influenza A  
> 5-16 18.6% 
Other Western countries     
CDC 
(Gershman), 
200522 
US 2004-2005 238 hospitalisations,  
< 18 yrs 
hospitalisation rate 
per 100 000 
population 
5-17 yrs 6.1 
CDC (Dhara), 
2005; CDC 
(Blanton), 
2007; CDC 
(Epperson), 
2008; CDC 
(Peebles), 2009 
21;23-25 
US 2004-2009 NR 4 year range 
hospitalisation rate 
per 100 000 
population 
EIP 
5-17 
 
2.3-6 
Dawood, 
201026 
US 2003-2008 4015 hospitalisation,  
< 18 yrs 
5 year range of 
hospitalisation rate 
per 100 000 
population  
5-17 yrs 3-8 
Public Health 
Agency of 
Canada, 2006; 
Reyes 2007; 
Burton, 2008; 
Reyes, 
200820;28-30 
Canada 2004-2008 1608 hospitalisations,  
< 16 yrs 
4 year range of 
proportion of 
hospitalised patients 
5-15 yrs 24.5%-34,2% 
Hassan, 200927 US 2003 (Jan-Dec) 20,618 hospitalisation 
without chronic diseases, 
<18 yrs 
proportion of 
hospitalised cases 
without chronic 
diseases 
2-18 yrs 55% 
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Table 14. Laboratory-confirmed seasonal influenza-related mortality in children 0–4 years old 
Author, year Country Season Study population Influenza 
hospitalisations 
No. of 
fatal 
cases 
Outcome 
measure  
Age group 
(years) 
Results 
Europe         
Montes, 
200532 
Spain 2001-2004 children 
hospitalised in a 
province in 
Spain, <5 yrs 
49 0  proportion of 
children among 
deaths 
0-4  0% 
Rojo, 200634 Spain 1996-2003 hospitalised 
patients in a 
hospital in 
Madrid, <3 yrs 
146 0 proportion of 
children among 
deaths 
0-2 0% 
Ploin, 200733 France 2002 (4 wks 
peak of 
epidemic) 
children visiting 
a paediatric 
emergency 
department,  
<3 yrs 
283 0 number of fatal 
influenza cases 
during follow up 
0-2  0% 
Other Western countries       
Burton, 
200820 
Canada 2006-2007 paediatric 
patients <16 yrs, 
large sample of 
paediatric 
hospitals in 
Canada 
371 2  proportion of 
children among 
deaths 
0-4 0% 
 
Dawood, 
201026 
US 2003-2008 large sample of 
US children  
<18 yrs 
4,015 17 proportion of 
children among 
deaths  
  
< 6 months 
6-23 months 
2-4 yrs 
3 of 
17(18%) 
1 of 17 
(6%) 
of 17 (18%) 
Roberts, 
200635 
Canada (Jan) 2004- 
(April) 2005 
children <16 yrs 
within the 
metropolitan 
Toronto and Peel 
region 
184 0 proportion of 
children among 
deaths 
0-4 0% 
D’Onise, 
200893 
Australia 1996-2006 paediatric 
population in 
South Australia, 
 <5 yrs 
649 4 proportion of 
fatal cases 
among 
hospitalised 
influenza cases 
0-4 4 of 649 
(<1%) 
Finelli, 2008; 
CDC 
(Epperson), 
200824;36 
US 2004-2008 all children  
<18 yrs in the 
US 
NR 249 proportion of 
fatal influenza 
cases, range 4 
seasons 
< 6 months 
6-23 months 
2-4 yrs 
11%-17% 
 8%-28% 
10%-20% 
 
Table 15. Laboratory-confirmed seasonal influenza-related mortality in children ≥ 5 years old 
Author, year Country Season Study population Influenza 
hospitalisations 
No. of 
fatal 
cases 
Outcome 
measure  
Age group 
(years) 
Results 
Other Western countries       
Dawood, 
201026 
US 2003-2008 Representative 
sample of US 
children < 18 yrs 
4,015 17 proportion of 
children among 
deaths 
5-17  10 (59%) 
      proportion of 
deaths among 
hospitalised 
cases 
0-17 17 of 4015 
(<1%) 
Roberts, 
200635 
Canada (Jan) 2004- 
(April) 
2005 
children < 16 yrs 
within the 
metropolitan 
Toronto and Peel 
region 
184 0  proportion of 
children among 
deaths 
5-15 0% 
CDC, 
(Epperson), 
2008; 
Finelli, 
200824;36 
US 2004-2008 all children <18 yrs 
in the US 
NR 249  proportion of 
fatal influenza 
cases, range 4 
seasons 
5-17 43-58% 
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Author, year Country Season Study population Influenza 
hospitalisations 
No. of 
fatal 
cases 
Outcome 
measure  
Age group 
(years) 
Results 
PHAC 2006; 
Reyes, 2007; 
Reyes, 2008; 
Burton, 2008 
20;28-30 
Canada 2004-2008 Representative 
sample of 
population  
<16 yrs, Canada 
1,608 11 4 seasonal mean 
(range) case 
fatality rate 
0-15 0.7%  
(0.4%-
1.3%) 
 
Table 16. Complications of laboratory-confirmed seasonal influenza in children 0–5 years old 
Author, 
year 
Country Season Study 
population  
No. of 
included 
cases 
Age 
group 
(years)  
Outcome measure Results 
Europe        
Forster, 
2004 
Germany 1999–2001 Paediatric patients 
of paediatric 
practices and 
referral children’s 
hospitals in four 
cities in Germany 
54 outpatients 
77 inpatients  
< 3 Proportion of outpatients 
with: 
• Croup 
• Bronchiolitis 
• Bronchitis  
• Pneumonia  
Proportion of inpatients 
with: 
• Croup 
• Bronchiolitis 
• Bronchitis 
• Pneumonia 
• Apnoea 
 
 
4.2% 
2.7% 
5.5% 
5.1%  
 
 
4.3% 
2.8% 
9.2% 
4.0% 
2.3% 
Montes, 
2005 
Spain 2001–2004 Children who 
were hospitalised 
for more than 24 
hours with 
confirmed 
influenza virus 
infection in three 
regions of Spain 
49 children  < 5 Proportion of cases with: 
• Bronchiolitis  
• Pneumonia  
• Bronchitis  
• Croup 
• ARI  
• Febrile syndrome with 
only minor respiratory 
symptoms (rhinorrhea, 
cough) 
  
24.5% 
18.4% 
6.1% 
2.0% 
26.5%  
22.4% 
Ploin, 2007 France 2002  
 
Children  
<36 months 
visiting the 
paediatric 
emergency 
department of a 
hospital in Lyon 
283 children  < 3 Proportion of cases with: 
• Rhinopharyngitis 
• Isolated fever 
• Otitis media 
• Bronchitis 
• Pneumonia 
  
54%  
22%  
6%  
6%  
0.4%  
 
Rojo, 2006 Spain 1996–2003 Hospitalised 
children <3 years 
in a hospital in 
Madrid 
117 hospitalised 
cases 
< 3 Proportion of cases with: 
• Pneumonia  
• Acute otitis media 
  
21% 
8.5% 
Other Western countries      
Krief, 2009 US 1998–2001 Infants in five 
different 
paediatric 
emergency 
departments 
123 infants  < 60 days 
of age 
Proportion of cases with: 
• Urinary tract infections 
• Wheezing 
• Bronchiolitis 
• Lobar pneumonia 
  
2.4%  
1.6% 
6.5% 
2.8% 
 
Poehling 
2006 
US 2002–2004 Patients of 
hospitals in two 
US counties 
160 hospitalised 
cases  
< 5 Proportion of cases with: 
• Otitis media 
• Pneumonia 
• Seizures 
  
28% 
6% 
1% 
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Table 17. Complications of laboratory-confirmed seasonal influenza in children 0–18 years old 
Author, year Country Season Study 
population  
No. of included 
cases 
Age group  
(years) 
Outcome measure Results 
Europe        
Heikkinen, 
200490 
 
Finland 2000-2002 Children  
<13 years in 
Finland 
370 children  < 13 Proportion of cases with: 
• Acute otitis media 
• Pneumonia 
• Sinusitis 
  
23%  
2.4% 
3.5% 
Lahti, 200695 
 
Finland 1980-2003 Paediatric 
patients of 
Department of 
Paediatrics, 
Turku University 
Hospital  
936 children  0-16 Proportion of cases with: 
• Pneumonia 
• Acute otitis media 
  
14% 
43% 
Ros Aranal, 
200896 
Spain 2002-2006 Children with 
influenza 
admitted to the 
Miguel Servet 
Children’s 
Hospitals in 
Zaragoza, Spain 
178 hospitalised 
cases 
< 15  Proportion of cases with: 
• Upper respiratory 
tract infection 
• Acute otitis media 
• Bronchitis/bronchiolitis 
• Pneumonia 
• Gastroenteritis 
• Myositis 
  
30.6%  
 
27%  
16.9%  
10.5% 
7.6% 
1.7% 
Tsolia, 
200697 
 
Greece  2003-2005 Outpatients  
>6 months to 
<14 yrs of a 
hospital and 
seven paediatric 
practices in 
Athens area 
573 outpatients  > 6 months-
<14 yrs 
Proportion of cases with: 
• Otitis media 
• Bronchial- asthma 
• Pneumonia 
• Croup 
• Febrile seizures 
  
15% 
8%  
1.7% 
1.7% 
1.6% 
Weigl, 
200219 
Germany 1996-2001 Children 
admitted to one 
of the local 
paediatric 
hospitals with 
any acute 
respiratory 
infection in Kiel 
102 influenza A 
patients  
 
0-16 Proportion of influenza A 
cases with: 
• Otitis media 
• Severe anaemia  
• Syncope  
 
  
 
25% 
1% 
1% 
 
14 influenza B 
patients 
 
 Proportion of influenza B 
cases with: 
• Otitis media 
• Myositis of the calf 
• Muscles 
  
 
0% 
7.1% 
 
Other Western countries      
Burton, 
200820 
Canada 2006-2007 Children  
< 16 yrs in 
Canada 
371 hospitalised 
cases 
< 16 Proportion of cases with: 
• Respiratory distress 
• Pneumonia 
• Croup 
• Otitis media 
• Myositis 
• Bacterial co-infection 
  
42%  
17% 
3% 
2% 
2% 
7% 
Dawood, 
201026 
US 2003-2008 Children  
< 18 yrs in the 
US 
4015 
hospitalised 
cases 
< 18 Proportion of cases with: 
• Pneumonia 
• Bacterial coinfection 
  
36% 
2% 
Finelli, 
200836 
US 2004-2005 All influenza-
associated death 
of patients  
<18 yrs in the 
US 
47 deaths 0-17 Proportion of influenza-
associated deaths with:  
• Bacterial coinfection 
  
 
6% 
  2005-2006  46 deaths 0-17  Bacterial coinfection 15% 
  2006-
2007 
 73 deaths 0-17  Bacterial coinfection 35% 
Newland, 
200798 
 
US 2000-2004 Paediatric 
patients 
admitted to a 
Hospital in 
Philadelphia 
842 hospitalised 
cases 
0-18* Proportion of cases with: 
• Seizures 
• febrile seizures 
• seizures with fever 
• other seizures 
• encephalopathy 
• Post-infectious 
encephalopathy 
  
7% 
3% 
1%  
2% 
1% 
0% 
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Author, year Country Season Study 
population  
No. of included 
cases 
Age group  
(years) 
Outcome measure Results 
Schrag, 
200699 
US 2003-2004 Hospitalised 
children  
<18 years in 54 
counties, 
including >100 
hospitals, in the 
US 
1,161 patients 
with influenza-
related 
hospitalisation 
not admitted to 
ICU 
0-17 Proportion of cases not 
admitted to ICU with: 
• Bacterial coinfection 
• Pneumonia 
• Bronchiolitis 
  
 
0.5% 
22% 
6% 
    147 patients with 
influenza-related 
hospitalisation 
admitted to ICU 
0-17 Proportion of cases 
admitted to ICU with: 
• Bacterial coinfection 
• Pneumonia 
• Bronchiolitis 
  
 
6% 
34% 
3% 
* 36 of the 842 cases were ≥ 18 years old. 
 
Table 18. Pandemic influenza A(H1N1) hospitalisations in pregnancy 
Author, year Country Season No. of 
hospitalisations in 
total study group* 
Outcome measure  Trimester Results 
Europe 
CDC, 201055 Greece 2009/2010 
(May-Feb) 
294 (ICU admissions) Proportion of pregnant 
women 
- 4.4%  
Cullen, 20094 Ireland 2009 (April-
Oct) 
180 Proportion pregnant 
women 
- 
 
6.7% 
Fuhrman, 
20101 
France 2009  
(July-Nov) 
244 severe cases of 
whom 
117 women 
Proportion pregnant 
women: 
• hospitalised women;  
• ICU cases 
-   
15.4%; 
13% 
Nguyen Van-
Tam, 20102 
UK 2009 
(April-Sept) 
631 • Proportion of pregnant 
women  
 
 
 
• Proportion of pregnant 
women in study 
population 16-44 yrs;  
• expected prevalence in 
source population 
1st  
2nd 
3rd  
unknown  
 
- 
0.3% 
2.1% 
1.3% 
0.6%  
 
18% of 
admissions 
 
6%  
Van ‘t Klooster 
20103  
 
The 
Netherlands 
2009 
 (June-Dec) 
• 1 722 non-ICU 
admissions (with 
information 
available)  
 
• 211 ICU 
admissions (with 
information 
available) 
Proportion of pregnant 
women 
1st  
2nd 
3rd  
Total  
 
1st  
2nd 
3rd  
Total 
0.2% 
0.9% 
2.1% 
3.5%  
 
0.5% 
0.5% 
2.4% 
3.8% 
Other Western countries     
ANZIC, 200960 Australia; 
New Zealand 
2009 (June-
August) 
722 ICU admissions Proportion pregnant 
women  
- 9.1% 
ANIZC, 201061 
 
Australia 2009 
(June-
August) 
209 childbearing age 
(15-44 yrs old) 
admitted to ICU 
Proportion of 
pregnant/postpartum 
women admitted to ICU  
 
-  
 
 
< 20 weeks 
≥ 20 weeks 
Postpartum 
31%  
 
 
15.6% 
76.6% 
7.8% 
CDC, 20096 US (Chicago) 2009 (April-
July) 
205 Proportion pregnant 
women 
- 7% 
Creanga, 
201056 
US 2009 (May-
June) 
976  • Proportion pregnant 
women  
• Hospitalisation rate 
pregnant women per 
100 000 population  
• Hospitalisation rate 
non-pregnant 
reproductive-aged 
women per 100 000 
population 
-  
 
-  
 
 
-  
 
6.4%  
 
55.3  
 
 
7.7 
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Author, year Country Season No. of 
hospitalisations in 
total study group* 
Outcome measure  Trimester Results 
Denholm, 
201057 
Australia 2009 (May-
July) 
112 of which 27 
admitted to ICU 
Proportion of pregnant 
women:  
• hospitalisations 
• ICU admissions  
-   
 
13%  
19% 
Fielding, 200959 Australia 2009 (April-
Sept) 
415 of which 108 ICU 
admissions 
Proportion of pregnant 
cases: 
• Ward-based 
• ICU admissions 
   
 
6.3% 
8.3% 
Hewagama, 
201062 
Australia 2009 (May-
July) 
43 pregnant women • Proportion pregnant 
women per trimester  
 
 
 
• Proportion ICU 
admissions  
 
• Estimated 
hospitalisation rate 
1st  
2nd 
> 28 wks 
> 37 wks  
 
-  
 
 
2nd 
3rd 
5% 
30% 
28% 
37%  
 
18.6%  
 
 
0.21%  
0.46% 
Jain, 20098 US 2009 (May-
June) 
272 hospitalisations 
of which 67 ICU 
admissions 
Proportion of pregnant 
women: 
• hospitalised 
• ICU  
• Proportion pregnant 
women per trimester 
  
 
-  
 
1st  
2nd 
3rd  
  
 
7% 
9%  
11% 
17% 
67% 
Kelly, 200958 Australia 2009 (May-
Oct) 
4833 of which 
650 ICU admitted 
Proportion pregnant 
women:  
• hospitalisations; 
• Rate per 100 000  
• ICU admissions 
• Rate per 100 000 
   
 
5.8% 
117.2  
47 
19.8 
Louie, 201063 US 2009 (April-
August) 
239 women 
reproductive age 
Proportion of pregnant 
women:  
• hospitalisations  
• Proportion pregnant 
women per trimester  
 
• ICU admission 
  
 
 
1st  
2nd 
3rd  
 
39.3%  
 
5% 
37% 
57%  
19% 
Siston, 201064 US 2009 (April-
Aug) 
509 pregnant women 
of which 115 ICU 
admitted 
Proportion of pregnant 
women: 
• hospitalisations  
 
 
 
• ICU admissions 
 
 
1st  
2nd  
3rd  
Unknown  
1st  
2nd  
3rd  
Unknown 
 
 
5.9% 
29.7% 
41.8% 
22.6%  
7.0% 
33.0% 
44.3% 
15.6% 
* All cases were laboratory-confirmed cases.  
 
Table 19. Pandemic influenza A(H1N1) mortality in pregnancy 
Author, year Country Season  Study 
population 
No. of fatal 
cases in total 
study group* 
Outcome measure  Trimester  Results 
Europe        
CDC, 201055 Greece 2009/2010 
(May-Feb) 
294 ICU 
admissions 
140 • Proportion pregnant 
women among 
deaths  
• Proportion of 
pregnant cases that 
died 
-  
 
 
- 
1 of 140 (0.7%)  
 
 
1 of 13 (7.7%) 
Fuhrman, 
20101 
France 2009 (July-
Nov) 
224 hospital 
admissions 
37 • Proportion pregnant 
women among 
deaths  
• Proportion of 
pregnant cases that 
died 
-  
 
 
- 
1 of 37 (2.7%)  
 
 
1 of 18 (5.6%) 
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Author, year Country Season  Study 
population 
No. of fatal 
cases in total 
study group* 
Outcome measure  Trimester  Results 
Nguyen-
Van-Tam, 
20102 
UK 2009 (April-
Sept) 
631 hospital 
admissions 
29 • Proportion pregnant 
women among 
deaths  
• Proportion of 
pregnant cases that 
died 
-  
 
 
- 
2 of 29 (6.9%)  
 
 
2 of 27 (7%) 
Pebody, 
201016 
England April 2009 – 
March 2010 
Population of 
England, all 
ages 
308 fatal cases 
with 
information on 
risk factors 
• Proportion pregnant 
women among 
deaths  
• Case fatality rate (per 
100 000 clinical 
cases) 
- 10 of 308 (3%)  
 
 
90 
 
Van ‘t 
Klooster 
20103  
 
The 
Netherlands 
2009 
 (June-Dec) 
2,186 hospital 
admissions (ICU 
and non-ICU) 
53  Proportion pregnant 
women among deaths  
 
- 0 of 53 (0%) 
Other Western countries      
CDC, 20096 US  2009  
(April-July) 
205 hospitalised 
cases 
7 • Proportion pregnant 
women among 
deaths  
• Proportion of 
pregnant cases that 
died 
-  
 
 
- 
14.3%  
 
 
1 of 14 (7.1%) 
Creanga, 
201056 
US 2009 (May-
June) 
976 hospitalised 
cases 
47 • Proportion pregnant 
women among 
deaths  
• Proportion of 
pregnant cases that 
died 
-  
 
 
- 
4.3%  
 
 
2 of 62 (3.2%) 
Fielding, 
200959 
Australia 2009  
(April-Sept) 
415 hospitalised 
cases  
24 Proportion pregnant 
women among deaths 
 
 
 
4.2% 
Jain, 20098 US 2009 (May-
June) 
272 hospitalised 
cases  
19 • Proportion pregnant 
women among 
deaths  
• Proportion of 
pregnant cases that 
died 
-  
 
 
- 
16%  
 
 
3 of 18 (16.7%) 
 
Kelly, 200958 Australia 2009  
(May-Oct) 
4833 
hospitalised 
cases 
186 • Proportion pregnant 
women - rate per 
100 000  
• Proportion of 
pregnant cases that 
died 
-  
 
 
- 
1.6% 
1.3  
 
3 of 278 (1.1%) 
Louie, 
201063 
US 2009  
(April-Aug) 
239 hospitalised 
women 
reproductive 
age 
25 • Proportion pregnant 
women among 
deaths 
• Maternal mortality 
ratio  
• Proportion of 
pregnant cases that 
died 
-  
  
 
- 
32%;  
 
 
4.3  
 
8 of 94 (8.5%) 
Siston, 
201064 
US 2009 
(April-Aug) 
788 H1N1 
pregnant cases 
of which 509 
hospitalised 
30 Proportion: 
• Pregnant women 
• Hospitalisations  
• Proportion of 
pregnant deaths per 
trimester 
-  
 
 
1st  
2nd  
3rd  
  
3.8% 
5.9%  
10% 
30%  
60%  
* All cases were laboratory-confirmed cases.  
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Table 20. Safety of influenza vaccines in children 
Author, 
year 
Country N Vaccine type Control Outcome measure Age group 
(months)  
Results*  
Esposito 
200640 
Italy 303 Inactivated, 
trivalent, 
virosome-
formulated 
subunit 
influenza 
vaccine 
No vaccination % of children with 
systemic/local AE 
2-5 years After first dose vs. second 
dose  
• Fever: 11.9% vs. 5.0%  
• Sneezing: 24.3% vs. 15.3% 
• Cough: 16.8% vs. 7.9% 
• Vomiting: 5.9% vs. 2.5% 
• Erythema/tenderness: 
6.9% vs. 7.9% 
• Total: 29.2% vs. 14.9% 
Kanra, 
200448 
Germany; 
Italy; 
Turkey 
453 Virosome-
adjuvanted 
Split vaccine % subjects with 
at least one 
systemic/local AE  
6 to 71  ≥ 1 systemic event virosome 
vs. split 
• 1st dose: 8.5% vs. 7.4% 
• 2nd dose: 4.6% vs. 7.0% 
• ≥1 local event virosome vs. 
split 
• 1st dose:8.9% vs. 4.8% 
• 2nd dose:4.6% vs. 5.1% 
Vesikari, 
200649  
Finland 197 LAIV Placebo % of subjects 
with solicited 
events within 10 
days of 
vaccination 
9-36  Vaccine vs. placebo 
• Rhinorrhea/nasal 
congestion: 80.2% 
vs.75.3% 
• Cough: 50.5% vs. 50.5% 
• Fever ≥38 °C: 51.2% vs. 
51.2%  
Vesikari, 
200642 
Belgium; 
Finland; 
Israel; 
Spain; 
United 
Kingdom 
Year 1: 
1616 
Year 2: 
1090 
CAIV-T Placebo • % of subjects 
with 
reactogenicity 
events (first 
dose year 1)  
 
 
• AEs (first dose 
year 1)  
 
 
• serious AEs 
possibly/ 
definitely 
vaccine related  
6 to < 36  CAIV-T vs. placebo;  
runny nose/nasal discharge:  
• 82.3 vs. 75.4%, (p=0.001) 
• Headache: 15.0 vs. 8.9% 
• Fever of >37.5 °C: 32.0 vs. 
27.8%  
 
• Fever: 8.7% vs. 7.2% 
• Rhinitis:8.2% vs. 8.0% 
• Cough: 6.4% vs. 7.9%  
 
– year 1: 9 vs. 5 subjects 
– year 2: 2 subjects in 
CAIV-T group 
Vesikari, 
200951 
Finland 222 Sub/MF59 Split vaccine % subjects with 
solicited 
local/systemic 
reactions; AEs** 
(possibly/probably 
vaccine related) 
6 to < 36  Sub/MF59 vs. split 
• Tenderness: 45% vs. 34% 
• Erythema: 35 vs. 27%  
• Induration: 16 vs. 14% 
• Irritability: 41 vs. 33% 
• Sleepiness: 27 vs. 19% 
• Analgesic/antipyretic use: 
26 vs. 23%  
• swelling 12% vs. 5%, 
(p=0.033)  
• 21 children in each group 
had a possibly/probably 
vaccine related AE 
Vesikari, 
200950  
 
Finland 89 Sub/MF59 Split vaccine % subjects with 
solicited 
local/systemic 
reactions, AEs 
16 to < 48  Sub/MF59 vs. split 
• Any: 79% vs. 59% 
• Local: 70% vs. 46% 
• Systemic: 42% vs. 37% 
• Other: 21% vs. 9% 
• Any AE: 70% vs. 76% 
• At least possibly/probably 
related AEs: 23% vs. 4% 
• Serious AEs: 0% vs. 0%  
• injection site pain in 
children ≥ 3 years old, 
p<0.01 
* The p-value was only mentioned if the result was significant. ** AE: Adverse Event: as defined/described in evidence table. 
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Table 21. Efficacy* of influenza vaccination in children 
Author, year Country N Vaccine type Control Outcome 
measure  
Age group 
(years)  
Results 
 
Esposito, 
200640 
Italy 303 Inactivated, 
trivalent, 
virosome-
formulated 
subunit 
influenza 
vaccine 
No vaccination Vaccine- 
efficacy in 
preventing 
influenza-like-
illness 
2-5 Upper respiratory tract 
infections: 33% 
Lower respiratory tract 
infections: 22% 
Febrile respiratory illnesses: 
26% 
Salleras, 
200641 
Spain 1951 Virosomal 
subunit 
inactivated 
influenza 
vaccine 
No vaccination Vaccine- 
efficacy in 
preventing 
influenza 
3-14 88.4% 
 
Vesikari, 
200642  
Belgium; 
Finland; 
Israel; Spain 
Year 1: 
1616 Year 
2:  
1090 
CAIV-T No vaccination Vaccine- 
efficacy in 
preventing 
influenza  
6 to  
< 36 months 
Year 1: 83.5% (against 
subtype influenza virus 
similar to vaccine); 83.8% 
(against subtypes influenza 
virus not similar to vaccine) 
Year 2: 89.0% (against 
subtype influenza virus 
similar to vaccine); 85.3% 
(against subtypes influenza 
virus not similar to vaccine) 
* Vaccine-efficacy: incidence rate in the vaccinated group divided by the incidence rate in the control group.  
 
 Table 22. Cost effectiveness of influenza vaccination in children 
Author, 
year 
Country N Vaccine type Control Outcome measure  Age group  
(years)  
Results 
 
Esposito, 
200640 
Italy 303 Inactivated, 
trivalent, 
virosome-
formulated 
subunit 
influenza 
vaccine 
No vaccination Net present value 
(from the individual 
perspective) 
2-5  
 
EUR +131.43  
 
Cost-benefit ratio 
(from the individual 
perspective) 
  
 
1.29  
Navas, 
2007100 
Spain 1000 Subunit 
virosomal 
influenza 
vaccine 
No vaccination Net present value 
(from the societal 
perspective) 
3-14  
 
EUR +7587.03  
 
Cost benefit ratio 
(from the societal 
perspective) 
 
 
1.80  
 
Net present value 
(from the provider 
perspective) 
 EUR -1460.51 
Salleras, 
2009101  
  
  
 
Spain 1000  
  
  
 
Subunit 
virosomal 
influenza 
vaccine 
No vaccination Reduction in cost-
generating events 
  
  
 
3-14  • Paediatric consultations: 
212.5 visits 
• Consumption of antibiotics 
and antipyretics: 58 
consumptions  
• Loss days of schooling 
avoided: 1039 days 
• Loss work days avoided: 
158.5 days 
net present value  EUR +21,551.62 
benefit-cost ratio 
(from a family 
perspective) 
 2.15 
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Annex 4. Levels of evidence 
 Intervention Diagnostic accuracy study Harm/side effects*, aetiology, prognosis 
A1 Meta-analysis or systematic review containing at least two trials of level A2, where the results of individual trials are 
consistent.  
A2 Randomised comparative clinical trials of 
good quality (randomised, double-blind, 
controlled trials) of sufficient size and 
consistency. 
Research evaluated with reference test 
(‘gold standard’) which met predefined 
cut-off values and an independent 
appraisal of test results and the gold 
standard, with a sufficient number of 
patients with both an index test and 
reference standard test. 
Prospective cohort study with a sufficient 
sample size and follow-up; adequately 
controlled for confounding and no 
selective follow-up. 
B Randomised clinical trials of moderate 
(weak) quality or insufficient size or 
other comparative trials (non-
randomised, cohort studies, patient-
control studies) 
Research evaluated with reference test, 
but not with all characteristics mentioned 
at level A2. 
Prospective cohort study, but not with all 
characteristics mentioned at level A2. 
C Non-comparative trials  
D Expert opinion 
* This classification is only applicable in situations where controlled trials are not possible due to ethical or other reasons. If a 
controlled trial is possible, the classification of intervention must be used. 
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Annex 5. CoCanCPG checklists for critical 
appraisal of literature 
 
Systematic reviews/meta-analyses 
 Internal validity 
The study addresses an appropriate and clearly focused question 
A description of the methodology used is included 
The literature search is sufficiently rigorous to identify all the relevant studies 
Study quality is assessed and taken into account 
Data extraction is clearly described 
The most important characteristics from the original research is described 
There are enough similarities between the studies selected to make combining them reasonable 
Statistical pooling is correctly performed 
Statistical heterogeneity is adequately taken into account 
Study quality is taken into account 
  
Overall assessment of the study 
Are the results of the systematic review valid? 
Are the results of the systematic review applicable to the patient group targeted in the search question? 
  
Comments 
Include or exclude 
If exclusion, give reason 
 
 
Randomised Controlled Trials 
  
Internal validity 
The study addresses an appropriate and clearly focused question 
The assignment of subjects to treatment groups is randomised 
An adequate concealment method is used 
Subjects are kept blind about treatment allocation 
Outcome assessors are kept blind about treatment allocation 
The treatment and control groups are similar at the start of the trial 
The only difference between groups is the treatment under investigation 
All relevant outcomes are measured in a standard, valid and reliable way 
All the subjects are analyzed in the groups to which they were randomly allocated (intention to treat) 
  
Overall assessment of the study 
Are the results of the study review valid? 
Are the results of the study applicable to the patient group targeted in the search question? 
  
Comments 
Include or exclude 
If exclusion, give reason 
 
Cohort study 
  
Internal validity 
The study addresses an appropriate and clearly focused question 
The cohort being studied is selected from source populations that are comparable in all respects other than the factor under 
investigation 
The likelihood that some eligible subjects might have the outcome at the time of enrolment is assessed and taken into account in the 
analysis 
Comparison by exposure status is made between full participants and those lost to follow up 
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The outcomes are clearly defined 
The assessment of outcome is made blind to exposure status 
The measure of assessment of exposure is reliable 
The main potential confounders are identified and taken into account in the design and analysis 
  
Overall assessment of the study 
Are the results of the study valid? 
Are the results of the study applicable to the patient group targeted in the search question? 
  
Comments 
Include or exclude 
If exclusion, give reason 
 
Case-control study 
  
Internal validity 
The study addresses an appropriate and clearly focused question 
The cases and controls are taken from comparable populations 
The same exclusion criteria are used for both cases and controls 
Cases are clearly defined and differentiated from controls 
Case ascertainment is performed blind from the exposure status 
Exposure status is measured in a standard, valid and reliable way 
The main potential confounders are identified and taken into account in the design and analysis 
  
Overall assessment of the study 
Are the results of the study valid? 
Are the results of the study applicable to the patient group targeted in the search question? 
  
Comments 
Include or exclude 
If exclusion, give reason 
 
Diagnostic accuracy study 
  
Internal validity 
The index test being studied is clearly specified 
The index test is compared with a reference standard 
The reference standard is likely to correctly classify the target condition 
The spectrum of the included patients is representative of the patients who will receive the test in practice 
Selection criteria are clearly described 
The time period between reference standard and index test is short enough to be reasonably sure that the target condition did not 
change between the two tests 
The whole sample or a random selection of the sample received verification using the reference standard of diagnosis 
Patients received the same reference standard regardless of the index test result 
The reference standard is independent of the index test (i.e. the index test did not form part of the reference standard) 
The execution of the index test is described in sufficient detail to permit replication of the test 
The same clinical data were available when test results were interpreted as would be available when the test is used in practice 
Uninterpretable/ intermediate test results are reported 
Withdrawals from the study are explained 
  
Overall assessment of the study 
Are the results of the systematic review valid? 
Are the results of the systematic review applicable to the patient group targeted in the search question? 
  
Comments 
Include or exclude 
If exclusion, give reason 
 
